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A CLINICAL COMPARATIVE STUDY BETWEEN 
DEXMEDETOMIDINE AND CLONIDINE AS AN ADJUVANT TO 
BUPIVACAINE IN BRACHIAL PLEXUS BLOCK BY 
SUPRACLAVICULAR APPROACH 
 
AIM OF THE STUDY  
Recently alpha 2 agonists are playing a vital role as an adjuvant in 
neuraxial block and peripheral nerve block. The purpose of this study is to 
compare the efficacy of Dexmedetomidine and Clonidine with Bupivacine 
in brachial plexus block by supraclavicular approach.  
MATERIAL AND METHODS :  
It is a prospective randomised single blinded study, conducted in 
unilateral upper limb surgeries under brachial plexus block. Patients were 
divided into two groups as Group B&C, GroupB&D, Group B&C (N=30) – 
35 ml of 0.357% Bupivacaine with Clonidine 2microgm/kg. Group B&D 
(N=30) - 35 ml of 0.357% Bupivacaine with Dexmedetomidine 
2microgm/kg.  
 
INCLUSION CRITERIA  
 ASA I, II  
 Age 20 to 50  
 Unilateral upper limb orthopaedic surgeries  
 Both sexes  
 
 
EXCLUSION CRITERIA  
 Patient Refusal  
 Patient  on  adrenoreceptor agonist or antagonist therapy.  
 Suspected coagulopathy  
 Infection at the site of block  
 History of  respiratory, cardiac, hepatic or renal failure.  
 Patients with medical complications like severe anemia, severe 
hypovolemia, shock, septicemia.  
 Allergy   to local anaesthetics and study drug.  
 Pregnant  women.  
 
Objectives:  
∗ Sensory block- onset time  
∗ Motor block-onset time  
∗ Complete duration of sensory and motor block  
∗ Total duration of analgesia  
∗ Adverse effects 
 
RESULTS: 
Comparison of quality of block 
Quality Mean SD p value t value 
 Group BC 3.13 0.82 
< 0.001 4.52 Significant 
Group BD 3.87 0.35 
 
  Bupivacaine dexmedetomidine group has better quality than 
bupivacaine clonidine group. 
 
Comparison of onset time of sensory block(minutes) 
 
Mean SD p value t value 
 
Group BC 8.47 1.04 
< 0.001 17.19 Significant 
Group BD 4.7 0.59 
 
  The mean time for onset of sensory block in Group BD was 4.7 
minutes which was lower than Group BC -8.47 minutes. This was 
statistically significant(p<0.05) 
 
Comparison of onset time of motor block between two groups 
  
OTMB Mean SD p' value t value  
Group BC 13.1 1.42 
< 0.001 11.32 Significant 
Group BD 9.63 0.89 
 
  The mean time for onset of motor block in Group BD was 9.63 
minutes which was lower than Group BC -13.1minutes.This was statistically 
significant(p<0.05). 
 
Comparison of total duration of sensory block between two groups (mt) 
TDSB Mean SD p' value t value 
 
Group BC 319.1 32.74 
< 0.001 25.89  
Group BD 537.8 32.67 Significant 
 
  The mean time for total duration of sensory block in Group BD was 
537.8minutes. This was higher than the Group BC -319.1minutes.It was 
statistically significant(p<0.05). 
 
Comparison of total duration of motor block between two groups 
TDMB Mean SD p' value Tvalue 
 
Group BC 222.23 17.84  
< 0.001 
40.27 Significant 
Group BD 466.87 28.08 
  
  The mean time for total duration of motor block in Group BD was 
466.87minutes. This was higher than in Group BC 222.23 minutes. It was 
statistically significant(p<0.05). 
 
Comparison of total duration of analgesia between two groups 
DOA Mean SD p value t value 
 
Group BC 375.23 32.6 
< 0.001 32.55 Significant 
Group BD 666.27 36.54 
 
  The total duration of Analgesia in Group BD was 666.27 minutes. 
This was higher than in Group BC – 375.23 minutes. It was statistically 
significant. (p<0.05). 
 
SUMMARY  
  In adult patients undergoing orthopaedic forearm and hand surgeries 
under brachial plexus block, the addition of 2μg/kg of dexmedetomidine to 
35 ml of bupivacaine (0.357%) produces a shorter onset time for sensory and 
motor blockade. It also prolongs the duration of sensory and motor blockade. 
Postoperatively the duration of analgesia is prolonged with minimal 
reduction in pulse rate,blood pressure. 
 
CONCLUSION 
  The addition of Dexmedetomidine (2μg/kg) to bupivacaine 
(0.357%) in  brachial plexus block by supraclavicular approach  results 
in a shorter onset time for sensory and motor blockade,  prolongs the 
duration of sensory and motor blockade and also the duration of 
analgesia. 
 
KEYWORDS : Supraclavicular block, Bupivacaine, Dexmedetomidine, 
Clonidine. 
 
 INTRODUCTION 
 
The surgeries in the upper limb can be done by general or regional 
anaesthesia or both. Nowadays  regional  anesthesia  have  wide 
application in providing surgical anaesthesia, complete muscle  
relaxation, better hemodynamic stability and  post  operative analgesia  
as  well  as  in  treating  chronic  pain  syndromes. The sympathetic 
block produced by regional anesthesia reduces vasospasm, edema. 
Nowadays most of the anaesthesiologists practicing combined general 
anesthesia and regional anesthesia in paediatric patients. It reduces the 
anesthetic requirements and provides smooth extubation.  
 
Regional anaesthesia has several advantages in the  postoperative  
period compared with general anaesthesia including decreased  sedation, 
decreased nausea and vomiting, early discharge from the  recovery room 
and  a  smooth  transition  to  pain  control as the  block  effects gradually 
dissipate.  
 
  Brachial plexus provide sensory innervations of the upper limb. 
William halsted first demonstrated the brachial plexus block by  axillary 
approach.1 There are various available approaches and  techniques  in  
brachial  plexus  blockade. 
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 These include  
a) Interscalene approach  
b) Supraclavicular approach  
c) Parascalene approach  
d) Axillary approach  
e) Infraclavicular approach  
 
LOCAL ANAESTHETICS 
  These  are  the  drugs  that  block  the  conduction  of  impulses  in 
the electrically excitable tissues. Local anaesthetics  provide  anaesthesia  
and  analgesia  by  blocking  the  transmission  of pain  sensation  along  
the nerve  fibres.  They are classified into  
 
1. Aminoamide group (Lignocaine, bupivacaine, levobupivacaine etc)  
2. Amino ester group (cocaine, Chloroprocaine, procaine, 
tetracaine)  
 
Bupivacaine is the commonly used local anaesthetic agent.  It is a 
racemic mixture with two enantiomers, levobupivacaine, S (-) isomer and 
dextrobupivacaine, R(+)isomer.  
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ADJUVANTS 
Adjuvants are added to local anaesthetic agents to  
- Prolong the duration of anaesthesia and analgesia  
- Reduces the dose requirement  
- Reduces the incidence of toxic effects(2)  
 
  Various adjuvants like morphine, fentanyl, sufentanil, 
dexamethasone, midazolam, ketamine,  neostigmine,  sodabicarbonate  
are added to local anesthetic agents. Alpha 2 receptor  agonists  clonidine 
and dexmedetomidine are of new interest in regional anaesthesia because 
of their better haemodynamic stability, sedation  and  longer duration of  
postoperative  analgesia.  
 
  Adjuvants  are  administered  by  various  routes  like  epidural,  
intrathecal  and  intravenous.  
 
DEXMEDETOMIDINE  
  Alpha 2 adrenergic receptor agonist dexmedetomidine gain the 
focus of interest for its sedative, analgesic, perioperative sympatholytic 
and hemodynamic stabilizing properties. Dexmedetomidine is a new 
highly selective alpha 2 adrenergic receptor agonist(3).  FDA approved 
dexmedetomidine as an ICU sedation for mechanical ventilation(4).  
Nowadays new researches are going on about dexmedetomidine as an 
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 excellent adjuvant in neuraxial blocks, peripheral nerve blocks and 
intravenous regional anaesthesia. Dexmedetomidine improves the quality 
of anaesthesia by means of fast onset, prolonged duration with sedative 
effect.  It provides excellent post operative analgesia, when compared to 
other adjuvants. 
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 AIM OF THE STUDY 
 
 Recently alpha 2 agonists are playing a vital role as an adjuvant in 
neuraxial block and peripheral nerve block.  The purpose of this study is 
to compare the efficacy of Dexmedetomidine and Clonidine with 
Bupivacine in brachial plexus block by supraclavicular approach. 
 
MATERIAL AND METHODS : 
  It is a prospective randomised single blinded study, conducted in 
unilateral upper limb surgeries under brachial plexus block. Patients were 
divided into two groups as Group B&C, GroupB&D, Group B&C (N=30) 
– 35 ml of 0.357% Bupivacaine with Clonidine 2microgm/kg. Group 
B&D (N=30) - 35 ml of 0.357% Bupivacaine with Dexmedetomidine 
2microgm/kg.   
 
Objectives: 
a) Sensory   block- onset time 
b) Motor block-onset time  
c) Complete duration of sensory and motor block 
d) Total duration of analgesia 
e) Side effects 
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 REVIEW OF LITERATURE 
 
  Swami SS et al(5) studied   the  efficacy  of  dexmedetomidine  
and  clonidine  with  bupivacaine  in  brachial  plexus  block  by 
supraclavicular approach. They  found  that dexmedetomidine  increases  
the  duration  of  motor  and  sensory  block  with  better  quality  and  
better  post  operative  analgesia  when  compared  to  clonidine 
  
  Rachana G et al(6)  studied  about  dexmedetomidine  with  
bupivacaine  in  brachial  plexus block  by  supraclavicular  approach. 
They  concluded  that  dexmedetomidine  provided  longer duration  of  
motor  and  sensory   block,  increased  duration  of  post  operative  
analgesia  and better  hemodynamic  stability  when  added  with  
bupivacaine 
 
  Sandhya agarwal, et al(7) compared   dexmedetomidine with 
bupivacaine in brachial plexus block by supraclavicular approach.  They 
concluded that dexmedetomidine hastens the onset time, increases the 
sensory and motor block duration and post operative analgesia. 
 
  Ammar AS et al (8) studied the effects of dexmedetomidine with 
bupivacaine in brachial plexus block by infraclavicular approach. The 
result was dexmedetomidine enhances the sensory and motor block onset 
time, increases the duration of analgesia, increases the sensory and motor 
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 blockade duration, produce less VRS (verbal response scale) pain scores 
and reduces supplemental opioid requirements when added with 
bupivacaine 
 
  Jang ho song et al (9) studied the effect of dexmedetomidine and 
epinephrine when added to 1%mepivacaine in infraclavicular brachial 
plexus block. They concluded that dexmedetomidine is a better 
alternative than epinephrine. 
 
  JE kim et al (1p0) studied the effects of dexmedetomidine with 
bupivacaine intrathecally in TURP surgery.  They concluded that 
dexmedetomidine produces fast onset, increases the sensory block 
duration and  post operative analgesia, but recovery of motor block could 
be delayed. 
 
  Deepika shukla et al(11) studied  the effects of dexmedetomidine 
and magnesium sulphate intrathecally with bupivacaine. They concluded 
that dexmedetomidine has rapid onset and prolonged duration than 
magnesium sulphate. 
 
  Rancourt et al (12) evaluated the effect of dexmedetomidine with 
ropivacaine  in posterior tibial nerve block. They conclude that sensory 
blockade is increased by dexmedetomidine. 
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   Cengiz Kaya et al (13) compared the effect of dexmedetomidine 
premedication intra muscularly on hemodynamics and stress response.  
They conclude that dexmedetomidine premedication reduces the dose of 
opioid requirement in induction and better post operative pain relief.   It 
also reduces the stress response. 
 
  Kaygusuz K et al(14) studied the efficacy of adding 
dexmedetomidine (1μg/kg) to levobupivacaine (0.5%) in axillary block. 
They concluded that dexmedetomidine shortens the onset time for 
sensory block , increases the duration of motor and sensory block and 
extends the post operative analgesia  
 
  Esmaoglu et al(15) evaluated the effects of dexmedetomidine 
(100μg) to levobupivacaine in axillary block. They found that 
dexmedetomidine decreases the onset time for motor and sensory block, 
extends the sensory and motor blockade duration and extends the duration 
of analgesia. 
 
  Feroz Ahmad Dar et al(16) did a study about dexmedetomidine 
added to ropivacaine in brachial plexus block by axillary approach.  They 
concluded that dexmedetomidine shortens the sensory and motor 
blockade onset time.  It also prolongs the duration of sensory and motor 
blockade and increases the duration of analgesia. 
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  Marhofer et al(17) did a study on the adjuvant action of systemic or 
perineural dexmedetomidine with ropivacaine in peripheral nerve block.  
They found that systemic and perineural dexmedetomidine increases the 
motor block duration by 10% and 60%.  
 
  Obayah et al (18) evaluated the effect of adding dexmedetomidine 
to bupivacaine for post operative analgesia in children who were operated 
for cleft palate repair.  He concluded that adding dexmedetomidine with 
bupivacaine for peripheral nerve block extends the postoperative 
analgesia   with clinically no relevant side effects.  
 
  Bajwa et al (19) studied the efficacy of fentanyl and 
dexmedetomidine to epidural ropivacaine for lower limb orthopaedic 
surgeries. They found that dexmedetomidine provides stable 
hemodynamics, early onset of sensory block, prolonged post operative 
analgesia, less consumption of local anaesthetics postoperatively and 
better sedation scores.  
 
  Al-mustafa et al (20) did a study of adding dexmedetomidine in 
lower dose to bupivacaine in spinal anaesthesia for urological procedures. 
They found that dexmedetomidine produces a dose dependent action in 
the onset and duration of sensory and motor blockade. 
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   Memis D et al (21) evaluated the efficacy of adding 
dexmedetomidine to lignocaine in intravenous regional anaesthesia.  They 
found that dexmedetomidine added to lidocaine produces the better 
quality of anaesthesia and perioperative analgesia without causing side 
effects.  
 
  M.A.Abosedira  et al (22) compared the effects  of clonidine and 
dexmedetomidine added to lignocaine in bier’ s block.  They concluded 
that dexmedetomidine lignocaine mixture enhances the quality of 
anaesthesia and improves tourniquet tolerance.  It also enhances the 
intraoperative and postoperative analgesia when compared to clonidine 
 
  Solanki S et al(23) compared the effects of dexmedetomidine and 
clonidine with bupivacaine in trauma patients posted for lower limb 
surgeries.  They observed that dexmedetomidine (5 μg) added to 
bupivacaine (15 mg) intrathecally provides longer duration of 
postoperative analgesia than clonidine(50 mcg).  
 
  Esmaoglu et al al (24) studied the effects of adding 
dexmedetomidine to lignocaine in bier’s block.  They found that 
dexmedetomidine added to lignocaine causes a better quality of 
anaesthesia and perioperative analgesia without any side effects.  
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 ANATOMY OF BRACHIAL PLEXUS  
 
  The brachial plexus provides innervation of the upper limb. 
The plexus consists of the roots, trunks, divisons, cords, terminal 
nerves. 
 
ROOTS :  
Roots are formed from the anterior primary rami of C5, C6, 
C7, C8 and T1.  In addition there may be contributions from C4 and 
T2.  If the plexus is formed from C4-C8, it is called as prefixed 
plexus.  If the plexus is formed from T2, then it is called as post 
fixed plexus.  The roots are joined together to form the trunks. 
 
 TRUNKS:  
• C5and C6 roots join to form the upper trunk  
• C7 root forms the middle trunk  
• C8 and T1 roots join to form the lower trunk.  
 
DIVISIONS:  
   Trunks are divided into ventral & dorsal divisions which 
supply the anterior and posterior aspects of the limb.  
 
 
 
 
 
11 
 
 CORDS : 
• Ventral divisions of the upper and middle trunk unites to form 
the lateral cord.  
• Ventral division of the lower trunk forms the medial cord.  
• Dorsal divisions of all the trunks unite to form the posterior 
cord.  
 
BRANCHES : 
Branches from the Root:  
1) Long thoracic nerve  (C5,C6,C7)   
   Motor supply- serratus anterior  
2) Dorsal scapular nerve  
    Motor supply-Rhomboids (C5) 
      Levator scapulae 
3) Nerve to subclavius 
 
Branches from the Trunk:  
1) Suprascapular Nerve (C5,C6)  
   Motor supply- supra spinatus & infra spinatus 
2) Nerve to Subclavius (C5,C6)  
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FIG.1 ANATOMY OF BRACHIAL PLEXUS 
 
Branches from the Cord:  
 Lateral cord:  
1) Lateral pectoral Nerve (C5,C6,C7)  
    Motor supply- pectoralis major and minor 
2) Musculocutananeous Nerve(C5,C6,C7)  
   Motor supply- Coracobrachialis, biceps, brachialis 
   Sensory supply-Lateral cutaneous nerve of arm 
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 3) Median nerve- Lateral root ( C5, C6,C7)  
 
 Medial cord: 
1) Medial pectoral Nerve (C8,T1) 
2) Medial cutaneous nerve of arm (C8,T1)& forearm(C8,T1)  
3) Ulnar nerve (C7,C8,T1) . 
a. Motor supply-Flexor digitorum profundus, Palmaris brevis, 
Flexor carpi ulnaris. 
b. Sensory supply-Dorsal and palmar cutaneous branches. 
c. Deep terminal branch of ulnar nerve  
Motor supply-Flexor digiti minimi, abductor digiti 
minimi, opponens digiti minimi, four palmar 
interossei, four dorsal interossei, two lumbricals, 
adductor pollicis. 
4) Medial root of median nerve(C8,T1)  
a. Motor supply- Pronator teres, flexor carpi radialis, flexor 
digitorum superficialis, Palmaris longus, lateral two 
lumbricals. 
b. Anterior interosseus branch: Flexor digitorum profundus, 
pronator quadratus, abductor pollcis brevis,  flexor pollicis 
longus, flexor pollicis brevis,  opponens pollicis. 
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 Posterior cord:  
1) Upper subscapular nerve(C5,C6)  
 Motor supply- subscapularis 
2) Thoraco dorsal  Nerve  
   Motor supply- Lattismus dorsi(C6,C7,C8)  
3)  Lower subscapular nerveC5, C6) 
           Motor supply-subscapularis  
4) Axillary nerve (C5,C6) 
a. Motor supply-Teres minor, deltoid  
b. Sensory supply- Upper lateral cutaneous nerve of arm  
5) Radial nerve(C5,C6,C7,C8,T1)  
a. Motor supply- Triceps, brachioradialis, extensor carpi 
radialis longus. 
b. Sensory supply- Posterior cutaneous nerve of arm and 
forearm, lower lateral cutaneous nerve of arm. 
c. Posterior interosseous branch of radial nerve 
Motor supply- Supinator, extensors of thumb 
d. Superficial branch of radial nerve  
Sensory supply- Dorsum of hand  
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Fig 2. Cutaneous distribution of cervical plexus and peripheral 
nerves 
 
ANATOMICAL LOCATION: 
   The plexus which is formed by the C5-C8, T1 nerve roots  are  
coming  from the corresponding intervertebral  foramen and passes 
behind the foramen transversorium. Then it lies between the anterior and 
posterior tubercles of the corresponding transverse process. The five roots 
are situated between the anterior and medial scalene muscles.  C5&C6 
roots unite to form the upper trunk, C7 continues as middle trunk, C8 
&T1 unite to form the lower trunk. 
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   The trunks emerge between the two scalene muscles and passes 
downwards and laterally across the base of posterior triangle and then it 
passes across the 1st rib.  At the lateral border of the 1st rib each trunk 
further divides into anterior and posterior division behind the clavicle.  
The anterior and posterior divisions unite to form the three cords.  
 
a) Lateral cord- it is formed by the anterior divisions of the upper and 
middle trunks. 
b) Medial cord- it is a continuation of the anterior division of the 
lower trunk. 
c) Posterior cord - formed by all the three posterior divisions.       
 
  Sympathetic contributions of this plexus are derived from middle 
cervical ganglion and stellate ganglion. 
 
Relations  
ROOTS 
  This part of the plexus lies above the second part of the subclavian 
artery and between the scalene muscles.       
           
TRUNKS 
In the posterior triangle, the trunks are covered by prevertebral 
fascia.  It is superficially placed, covered by skin, platysma and deep 
fascia. 
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 Structures crossing the trunk: 
  Omohyoid-Inferior belly 
  External jugular vein 
  Transverse cervical artery 
  Supraclavicular nerves 
 
  The upper and middle trunks are situated above the subclavian 
artery as they pass across the first rib. The lower trunk lies behind the 
artery and may groove the rib immediately posterior to the subclavian 
groove. 
 
DIVISIONS 
  At the level of lateral border of first rib and behind the clavicle, 
subclavius muscle, suprascapular vessels (which lies immediately 
posterior to the clavicle), the trunks are bifurcate into divisions and then it 
descends into the axilla. 
 
CORDS: 
  Cords are formed at the apex of the axilla. These cords are named 
in relation to the axillary artery. Lateral cord- lateral to the axillary 
artery.Posterior cord- At first it lies lateral to the artery, when it comes 
behind the pectoralis minor it lies posterior to the artery. Medial cord- At 
18 
 
 first it lies behind the artery, but when it comes behind the pectoralis 
minor it lies medial to the artery. 
 
History: 
• In 1880 von anrep had injected cocaine under the skin of his arm 
and he realised the insensitivity of that area. 
• 1879&1880 –william halsted and Alfred hall injected 4%cocaine in 
the forearm.  They found that it produces analgesia below the level 
of injection and not above. 
Then hall injected 2ml into the ulnar nerve at the level of 
elbow.  It produced loss of sensation along the ulnar 
distribution. 
• After 1893, George crile, surgically exposed the neck and injected 
each nerve directly. 
• G.Hirschel first discovered the axillary approach. 
• D.Kulenkampff first discovered the supraclavicular approach. He 
injected 10 ml of procaine in midclavicular area lateral to 
subclavian pulse. 
• L.Bazy and V.Pauchet 1917-introduced infraclavicular approach  
• Intravenous regional anesthesia was first introduced by August bier 
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 SUPRACLAVICULAR BLOCK: 
Indications: 
 Surgery on distal upper extremity 
 To palliate acute pain emergencies, herpes zoster, neuritis, 
upper extremity trauma, cancer 
 Alternative to stellate ganglion block 
Blockade level occurs at distal trunk- proximal division level. 
 
ADVANTAGES: 
• compactly  arranged   nerve  fibres 
• intensive  blockade  
• Small volume of drug 
• Rapid onset of reliable blockade 
• Can be performed with patients arm in position. 
 
DISADVANTAGES: 
• Less suitable for shoulder  problems, requires cervical plexus 
block for supplementation 
• Demonstrable  paraesthesias  required which is unpleasant 
for the patient 
• 0.5 - 6% of pneumothorax  incidence seen 
• 40-60% phrenic nerve blockade  seen 
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 • 70-90% stellate ganglion blockade  recorded 
• Possibility of neuritis also seen. 
 
Various Technique: 
Classic approach    :  Kulenkampef 
Subclavian perivascular approach :  Winnes and Collins 
Modified lateral paravascular approach of Moorthy 
 
Technique  
  Several anatomic points are important in performance of the 
supraclavicular approach. The trunks are situated vertically at the level of 
the first rib, with the relation to the subclavian artery cephaloposteriorly, 
which can often be palpated in a slender, relaxed patient. At the level of 
the midpoint of the clavicle, the neurovascular bundle lies inferiorly. The 
1st rib acts as a medial barrier to the needle reaching the pleural dome and 
is short, broad, and flat, with an anteroposterior orientation at the site of 
the plexus. 
 
Position :  supine, 
   Head turned to the opposite side 
            Arm in adducted position, hand should be extended towards the 
same side of the knee. 
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 Classical technique :- Identify and mark the  midpoint of the clavicle.  
The posterior border of the sternocleidomastoid can be palpated easily  
when the patient raises the head slightly. Then palpate the belly of 
scalenus anterior muscle, in the interscalene groove which may be 
situated at the level of midpoint of the clavicle around 1.5 – 2 cm 
posteriorly.  We can palpate the subclavian pulse at this level.  
 
 
FIGURE 3 SUPRACLAVICULAR BLOCK 
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   After appropriate preparation, a skin wheal should be created at the 
landmark.  A 22-gauge, 4-cm needle is inserted lateral and posterior to 
the subclavian pulse in a caudal, medial and posterior direction until the 
paresthesia or motor response is elicited or the first rib is encountered.  If 
a syringe is attached, this causes the needle and syringe to lie parallel to a 
line joining the skin entry site and the patient's ear. If the first rib is 
encountered without paresthesia, the needle should be systematically 
walked anteriorly and posteriorly along the first rib until the plexus or the 
subclavian artery is located, which results in a paresthesia or motor 
response. After confirming negative aspiration for blood, the local 
anesthetics are injected incrementally. 
 
  The rib is usually contacted at a needle depth of 3 to 4 cm.  
However, in an obese patient or in the presence of tissue distortion from 
hematoma or injection of solution, the depth may exceed the length of the 
needle. Nonetheless, before the needle is advanced farther, gentle probing 
in the anterior and posterior directions should be done at the 2- to 3-cm 
depth if paresthesias are not obtained. Multiple injections may improve 
the quality or may shorten the onset of blockade. 
 
  The modified plumb-bob approach uses similar patient positioning, 
although the needle entry site is at the point where the lateral border of 
the sternocleidomastoid muscle inserts into the clavicle. After preparation 
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 and raising of a skin wheal, a 22-gauge, 4-cm needle is inserted while 
mimicking a plumb-bob suspended over the needle entry site. Frequently, 
a paresthesia or motor response is elicited before contacting the first rib 
or artery. If no paresthesia or motor response is elicited, the needle is 
reinserted while angling the tip of the needle cephalad and then caudad in 
small steps until the first rib is contacted.  The modified plumb bob 
technique reduces the unwanted complications of classic approach(26). 
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FIGURE 4 PLUMB BOB TECHNIQUE 
 
NERVE IMAGING STUDY WITH ULTRASOUND: [25-30] 
  The Fascicles of peripheral nerves can be detected with a high-
resolution ultrasound imaging.  The fascicular echotexture is often the 
most distinguishing feature of nerves namely “honeycomb” architecture.  
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 More central nerves, such as the cervical ventral rami, with fewer 
fascicles,   therefore can appear as   monofascicular on ultrasound scans.   
 
  One of the most powerful techniques to clinch the nerve fascicles is 
to slide a broad linear transducer   on the area of     peripheral      target 
nerve.  
 
  Nerves can appear round, oval, or triangular.   Although nerve 
shape can be   changing     on   course, cross-sectional area is same and 
constant in the absence of major branching.  The Peripheral nerves are 
pathologically enlarged also by entrapment or in certain other 
neuromuscular disorders such as Charcot-Marie-Tooth disease of type IA.  
There is also some evidence to suggest that the   patients with diabetic 
neuropathy are   also having enlarged peripheral nerves. 
 
  It is true that direct nerve imaging has led to a phenomenal good   
increase in ultrasound-guided regional anesthesia, but still the 
identification of other nearby structures like the fascia and other 
connective tissue is critical in this endeavor. 
 
  These significant structures permit favorable distribution of local 
anaesthetic that the nerve contact with the block needle is not mandated. 
Successful drug injections   must always clarify the borders of the nerve. 
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 ULTRASOUND AND ITS ARTIFACTS IN REGIONAL 
ANAESTHESIA: (31-41) 
  There are several common assumptions in the ultrasound imaging.  
First of all, the velocity of sound is assumed to be around 1540 msec.  
This estimate was achieved from measurements   on   soft     tissue at 
physiological   body temperature.  
 
   When   the    local heterogeneities exist, then artifactual bending of 
the block needle can be seen with sonography, the so-called bayonet 
artifact.  The Speed of sound artifacts relate to the   time-of-flight 
considerations and to the refraction at the interface of tissues with   the 
different speeds of sound. [33,34,35]  
 
  Comet tail artifact is a type of reverberation artifact.  At   the   low 
receiver gain, the comet tail is seen as a typical tapering series of discrete 
and clear echo bands just deep to a strongly reflecting structure.  
 
  Then spacing between the bands represents the distance seen   
between the anterior and posterior   side   walls of the object.  Internal 
clear reverberations which arising from within the object cause the artifact 
of comet tail, that is most intensely observed while   the object is 
perpendicular to the beam.  
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  Moreover the pleura is a strong reflector that causes the comet tail 
artifact.   Reverberation echoes are usually seen while strong specular 
reflections are being received.    
            
  During supraclavicular block, the mirror-image artifacts can be 
observed from the reverberation.  While the pleura is adjacent to the 
subclavian artery, the   mirror-image artifacts can occur with gray-scale 
type sonographic imaging. 
 
  Third to say, all reflectors are assumed to be on one central ray of 
the transducer beam.  When this is not occurring true, out-of-plane 
artifacts are also observed that are slice thickness artifacts. 
 
  Definitive proof of the out-of-plane artifacts requires multiple 
views that are recommended when ambiguities arise. 
 
  Not like the adjacent tissue, biologic fluids are not significantly 
attenuating the sound beam and therefore will cause acoustic 
enhancement. The Acoustic enhancement artifacts deep to vessels may   
be erroneously interpreted as the nerves.  For example, acoustic 
enhancement lying deep to the axillary artery  that  is  in  the axilla can  
mislead. 
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 PHYSIOLOGY OF NERVE CONDUCTION  
  
  Autonomic postganglionic efferent and nociceptive afferent C 
fibres are nonmyelinated. These axons have only single Schwann cell 
sheath.  Large motor and sensory fibres are myelinated.  The myelin 
sheath enhances the nerve conduction and causes the action potential 
impulse to flow through the axoplasm to node of Ranvier.  Active 
impulses are regenerated in nodes of Ranvier.  Sodium channels are rich 
in nodes of Ranvier in myelinated nerve fibres.  These channels are 
essential for impulse generation and propagation(42).   In unmyelinated 
nerve fibers, these sodium channels are present throughout the length. 
 
Physiology of nerve conduction: 
  The Nerve cells   maintain a negative resting potential difference of 
-60 to -90mv. During rest, it is impermeable to sodium ions and 
permeable to potassium ions. This gradient was maintained by 
Na+K+ATPase (transport of three sodium ions out of the cell for two 
potassium ions into the cells).  Permeation of these ions occur via an ion 
channel, a specialised protein. 
 
Action potential:   
  During the stimulus, the nerve cell membrane permeable to sodium 
ions and changing the membrane potential to positive(43) .  The threshold 
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 for sodium ion channel opening is -55mv.  During depolarisation, both 
sodium and potassium ion channels are in open configuration (Na>K). So 
excessive positive ions enter intracellularly and reversal of membrane 
potential to +35mv.  The membrane depolarization extends to nearby the 
area and cause more opening of sodium channels and increasing the 
inward current.  This event continues until some of the sodium channels 
became inactivated and also k+ channels are still opened and result in a net 
outward current and produces repolarization.  Now the threshold above 
the resting state, so it is refractory to next stimulus.  Over time, the 
sodium channel inactivation decays and the potassium channel changes to 
closed state.  Thus the resting threshold is restored. 
 
  Sodium channel has one large alpha subunit and one or two small 
beta subunits.  Alpha subunit has four domains which is homologous DI-
DIV and each has six helical regions (S1-S6) to span the membrane.  It 
was in three states, open, inactivated and resting state.(44-45) 
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FIGURE 5 STRUCTURAL FEATURES OF SODIUM CHANNEL 
 
LOCAL ANAESTHETICS 
Local anesthetics bind with alpha subunit and block from inside of 
the cell (Tetrodotoxin which binds and block from outside of the cell).  
Local anesthetics does not alter the resting membrane potential.   When 
increasing the concentration of local anesthetics, it slows the impulse 
conduction  and decrease the rate of rise and magnitude of the action 
potential and threshold for excitation is raised progressively.  Thus the 
propagation of impulse is abolished. 
 
  Local anesthetics have greater affinity to activated and inactivated 
state than the resting state.  Its action is both voltage and time dependent. 
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 Frequency dependent blockade: (46,47) 
  Local anesthetic action is effective, when the nerve fibres are 
activated rapidly.  Also called as use dependent blockade or phasic block.   
 
More depolarization causes more affinity with local anesthetics. 
a) Guarded receptor model: This theory states that binding sites 
are more available during firing of nerve. 
b) Modulated receptor model: Local  anesthetics dissociates 
from inactivated channels slowly than from resting 
channels.(48) 
 
Order of sensitivity to local anesthetics (49) 
a) Small myelinated axons A γ ,Aδ  
b) Large myelinated  Aα,  Aβ 
c) Small non myelinated C fibres. 
 
Other channels blocked by the local anaesthetics: Calcium, Potassium, 
NMDA  
   
Structure of local anaesthetics: 
It has three groups  
1) Lipophilic – benzene ring 
2) Hydrophilic end – tertiary amine 
3) Intermediate chain  by ester /amide  
32 
 
  
  These local anesthetics are weak bases. Lipid solubility determines 
the potency. Local anaesthetics are poorly soluble in water, but soluble in 
hydrophobic organic solvents.  So these drugs are prepared as water 
soluble hydrochloride salts with a PH of 6-7. Potency is determined 
mainly by lipid solubility(50).  
 
  Epinephrine is unstable in alkaline solution. So commercial 
preparations of local anaesthetics with adrenalin solutions are available as 
acidic solution(PH4-5). 
Aminoester  :  Procaine, Chloroprocaine, Tetracaine, Cocaine  
Aminoamides :  Lignocaine, Bupivacaine, Ropivacaine,  
   Mepivacaine, Prilocaine, Editocaine. 
 
  Cm- minimum concentration of local anesthetic that will block the 
nerve impulse conduction.  Factors determining the cm are fibre size, 
type, myelination, PH(acidic PH antagonize the block), frequency of 
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 nerve stimulation, electrolytes level.  (hypokalemia, hypercalcemia 
antagonize block)(51). 
 
  Onset of action depends on lipid solubility and concentration of 
non ionized form. Local anesthetics with pka closest to physiological PH 
will have a higher concentration of non ionized base and have the fast 
onset property. Increasing the dose or concentration of local anesthetics 
cause prolonged duration of action and reduce the onset time(52,53). But it 
will cause local anesthetic toxicity.  Adjuvants are added with local 
anesthetics to avoid the side effects of local anesthetics and improve the 
efficacy and onset.  
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 PHARMACOLOGY OF BUPIVACAINE 
 
 
 
  Bupivacaine is an amide type of  local anaesthetic drug.  It is a 
hydrochloride salt of 1-butyl-N-(2, 6-dimethylphenyl) piperidine-2- 
carboxamide.  
 
   It was synthesized in Sweden by Ekenstam and his colleagues in 
1957. First used clinically by L.J. Telivuo in 1963. Pka is 8.2 
 
Molecular weight     -  288 
Protein binding     -  95% 
Lipid solubility     -  28 
Elimination half life   -  210mts 
Toxic plasma concentration   -  >1.5µg/ml 
Approximate duration of action  -  175mts 
 
  The drug is very stable to acids, alkalis and repeated autoclaving.  
Bupivacaine 0.5% is the preferred strength.  Higher concentration result 
in greater variability of spread.  Bupivacaine is 4 times potent than 
lidocaine, hence 0.5 % solution is equivalent to 2 % lidocine.  It is more 
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 cardiotoxic than lidocaine. Cardiotoxicity is aggravated by hypoxia, 
hypercapnia and pregnancy. It causes less motor block compared to 
sensory block.  It is not recommended for intravenous regional analgesia.  
Duration of action is between 5 to 16 hours and is the longest acting local 
anaesthetics, which is related to binding to nerve tissue. Small percentage 
of a given dose of drug is excreted unchanged in the urine and the 
remainder is metabolized in the liver.  
 
Uses: 
 Spinal anaesthesia 
 Epidural anaesthesia 
 Caudal anaesthesia 
 Continuous epidural anaesthesia 
 Peripheral nerve block 
 Infiltration anaesthesia 
 
Onset time and duration of action 
 
Site of action Onset (minutes) Duration (minutes) 
Intrathecal 5 90-120 
Epidural 15-20 165-225 
Brachial plexus 10-20 600 
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 Pharmacokinetics: 
  Once injected intrathecally, it gets absorbed by the nerve rootlets 
and it is rapidly absorbed from the site of injection, but the rate of 
absorption depends on the vascularity and the presence of 
vasoconstrictors. Because of high lipid solubility it easily penetrates 
nerve and vascular tissue. 80-95% of absorbed bupivacaine binds to the 
plasma proteins. 
 
Distribution: 
 Rapid distribution phase: (α)  
 Slow disappearance phase: (β) 
 
Biotransformation: 
  Possible pathways of metabolism of bupivacaine include aromatic 
hydroxylation and conjugation. Only the N-dealkylated metabolite, N-
desbutyl bupivacaine has been measured in blood or urine after 
epidural/spinal anaesthesia. Alpha1 acid glycoprotein is the most 
important plasma protein binding site of bupivacaine and its 
concentration is increased by many clinical situations including post 
operative trauma. 
 
Excretion: 
 4-10% of the drug is excreted in urine as  unchanged form. 
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 Mode of action 
 Site of action: 
 The spinal nerve rootlet fine nerve filaments having a large 
surface area   are exposed to the local anaesthetics. 
 Posterior and lateral aspects of the spinal cord. 
 
 Sodium Channel blockade: 
  They impede the sodium ion access to the axon interior by 
occluding the transmembrane sodium channels, thus delaying the process 
of depolarization and  the axon remains polarized. It is a non-
depolarisation blockade. Thus the resting membrane potential is 
maintained and depolarization in response to stimulation is inhibited. 
 
  The mechanism by which local anaesthetics block sodium channel 
conductance is as follows, 
a) Local anesthetics in the cationic form act on the receptors within 
the sodium channels, on the cell membrane and block it. The local 
anaesthetic can reach the sodium channel either via the lipophilic 
pathway directly across the lipid membrane or via the axoplasmic 
opening. This mechanism accounts for 90% of the nerve blocking 
effects of amide local anaesthetics. 
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 b) The second mechanism of action is by membrane expansion.  This 
is a non specific action in contrast to the more specific drug 
receptor interaction. 
 
Pharmacodynamics: 
  It has got a longer duration of action but a slower onset. 
 
Cardiovascular system: 
  Bupivacaine reduces the cardiac output by reducing the 
sympathetic tone, by slowing the heart rate and by reducing the venous 
return.  It produces a fall in arterial blood pressure, but it is relatively 
slow and is seldom very profound.  Central venous pressure is reduced.  It    
causes an increase in lower limb blood flow, thereby it reduces the 
incidence of deep vein thrombosis. 
 
Respiratory System: 
  It relaxes the bronchial smooth muscle. It causes apnea due to 
phrenic and intercostal nerve paralysis or depression of the medullary 
respiratory center following direct exposure to drug. 
 
Gastro intestinal tract: 
  There is an increase in gastro intestinal motility and emptying of 
the gastric contents. 
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 Toxicity: 
  Toxicity is related to the plasma level of unbound drug and more 
likely due to an inadvertant intravenous injection. Systemic toxicity 
reactions primarily involve central nervous system and cardio vascular 
system. The blood level required to produce central nervous system 
toxicity is less than that required to produce circulatory collapse. 
 
Central Nervous System Toxicity: 
  The patient may have circumoral numbness, dizziness and tongue 
paresthesia immediately. Tinnitus and blurred vision may follow.  
Excitatory signs such as restlessness, agitation, nervousness, paranoia will 
precede central nervous system depression (slurred speech, drowsiness, 
unconsciousness). Muscle twitching followed by tonic clonic seizures. 
Respiratory arrest often follows.   Selective blockade of inhibitory 
pathways causes these excitatory reaction. 
 
Cardiovascular System Toxicity(54-56) 
  The rate of depolarization in fast conducting tissue of purkinje 
fibres and ventricular muscle is decreased. The rate of recovery of 
bupivacaine induced block is slower than that of lignocaine.  Extremely 
high concentration of the drug causes sinus bradycardia, hypotension, 
atrioventricular heart block, idioventricular rhythms and life threatening 
arrhythmias such as ventricular tachycardia, ventricular fibrillation and 
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 cardiac arrest. Levobupivacaine  S(-) isomer  is  devoid  of  some of  the 
CNS  and CVS  adverse  effects. It  will prevent  the  toxic  effects  
following  inadvertent  intravascular  injection  of  bupivacaine.   
 
The dosage of bupivacaine depends on, 
 Area to be anaesthetized 
 The vascularity of the tissue to be blocked 
 The number of neuronal segments to be blocked 
 Individual tolerance 
 Technique of local anaesthesia. 
 
Available concentrations: 
 0.25%,0.5% 
 0.25%,0.5% soluble in isotonic saline 
 0.5% 0.75% solution in 8% dextrose hyperbaric 
 These doses can be repeated in 3-4 hours but maximum dose is 
400mg in 24 hours. 
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 Dosage and concentration of bupivacaine in various blocks 
Type of block Concentration Dosage in ml Dosage in mg 
Local infiltration 0.25-0.5% 5-20ml Upto 75 mg 
Brachial plexus 
block 
0.25-0.5% 20-40ml 75-225 mg 
Intercostal block 0.25-0.5% 3-5ml 
15-20mg per each 
nerve 
Epidural block 0.25-0.5% 15-20ml 50-200mg 
Caudal block 0.25-0.5% 15-30ml 75-150mg 
Subarachnoid 
block 
0.5% 2-4 ml 10-20mg 
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 PHARMACOLOGY OF DEXMEDETOMIDINE 
 
  Dexmedetomidine is an ∝2- agonist that received FDA approval in 
1999.  It is used as a short-term sedative analgesic especially in the ICU 
and usually not used for more than 24 hours(57).  Dexmedetomidine is a 
selective ∝2 – adrenoceptor agonist. It is used in high doses for sedation 
and analgesia.  It has a reversal drug Atipamezole for  its  sedative effect. 
It is used in perioperative period as sedative and analgesic, as 
premedication, as an anesthesic  adjunct  for general  as well as regional 
anesthesia  and  also  for  post  operative  sedative  and  analgesic. 
 
Physiology of ∝2  -adrenoceptors. 
  Alpha 2 – adrenoceptors  are  found  in  peripheral   and  central  
nervous systems,  also  in  effector  organs  like   liver,  kidney,  pancreas, 
eye,  vascular  smooth  muscles  and  platelets. 
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 They are divided into 3 subtypes. 
 ∝2 A- predominant subtypes in CNS, this is responsible for  the 
sedative, analgesic and sympatholytic effect. Dexmedetomidine  is  
8  to  10  times  more  selective  towards  ∝2 AR  than  Clonidine.   
 ∝2 B –found mainly in the peripheral vasculature, and  is  
responsible  for  the  short term hypertensive  response. 
 ∝2 C-found  in  the  CNS, which  is  responsible  for  the  
anxiolytic effect(58) ,startle  response.  
 
  Startle response is the response of mind and body to a sudden 
unexpected stimulus, such as flash of light, loud noise.  In human beings, 
the reaction includes physical movement away from the stimulus, the 
contraction of the muscles of arms and legs,blinking , respiratory and 
blood pressure changes. 
 
 
Fig 6 preganglionic and postganglionic alpha receptors of 
sympathetic nervous system 
44 
 
   All these subtypes produce cellular action by signalling through a 
G-Protein which couples to effector mechanisms, and the coupling differs 
depending on receptor sub-type and location. The ∝2 A-Subtype appears 
to couple in an inhibitory fashion to the calcium channel in the locus 
ceruleus of the brain stem and in the vasculature.  The ∝2 B subtype 
couple in an excitatory manner to the same effector mechanism. 
 
Mechanism of action of dexmedetomidine: 
  Dexmedetomidine possess unique properties and it differs from 
other sedative drugs. ∝2 – adrenoceptors are found in many sites 
throughout the CNS, but the highest densities are found in the locus 
ceruleus, the predominant noradrenergic nuclei of the brainstem which is 
an important modulator of vigilance(59). Presynaptic activation of ∝2 
adrenoceptor in the locus ceruleus inhibits nor epinephrine (NE) release 
and results in sedative and hypnotic effects. Locus ceruleus is the site of 
origin for descending medullospinal noradrenergic pathway which is an 
important modulator of nociceptive neuro transmission. Stimulation of 
the ∝2 –adrenoceptors in this area terminates mainly the propagation of 
pain signals leading to analgesia. Post synaptic activation of ∝2 – 
adrenoceptors in the CNS causes decrease in sympathetic activity which 
leads to hypotension and bradycardia. Also cardiac vagal activity is 
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 augmented and all the effects together produce analgesia, sedation and 
anxiolysis. 
 
  Stimulation of ∝2 –receptors at the substantia gelatinosa causes 
inhibition of the  nociceptive neurons  firing and inhibition of  substance 
P release.∝2adrenoceptors also have analgesic mechanisms by inhibiting 
norepinephrine release at the nerve endings whereas the reason for 
analgesic effect is by the spinal mechanism.  
 
  ∝2 - Receptors located on blood vessels which mediates 
vasoconstriction whereas those located on sympathetic terminals inhibit 
norepinephrine release. In other areas these ∝2 adrenoceptors cause 
contraction of vascular and other smooth muscles, decreased salivation, 
secretion and bowel motility in the gastrointestinal tract.  It also inhibit  
the release of  renin , increased glomerular filtration rate, decreased 
insulin release from pancreas, decreased intraocular pressure, decreased 
platelet aggregation and decreased shivering threshold by 2oC.(60) 
 
Pharmacokinetics: 
Absorption and distribution: 
  Dexmedetomidine with the dose of 0.2 to 0.7 µg/kg /hr exhibits 
linear pharmacokinetics and it is administered as intravenous infusion 
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 upto 24 hours. Also it has the rapid distribution phase, its distribution half 
life is around 6 minutes (61), and elimination half life is 2 hours. 
 
  The volume of distribution is 118L.   Average protein binding is 
94%. Context- sensitive half life ranges from 4 minutes after a 10-minute 
infusion to 250 minutes after an 8-hour infusion. Its oral bioavailability is 
poor, which is because of extensive first-pass metabolism. The 
bioavailability of sublingual route is high (84%) and it offers a potential 
role in pediatric sedation and premedication. 
 
Metabolism and excretion 
  Dexmedetomidine undergoes biotransformation through direct N- 
glucuronidation and cytochrome P-450 (CYP 2A6) mediated aliphatic 
hydroxylation to its inactive metabolites. Metabolites are excreted in the 
urine(95%) and in the feces (4%). Dose has to be reduced in patients with 
hepatic failure. 
 
Pharmacodynamics  
  ∝- adrenoceptor agonists have different ∝2 / ∝1 selectivity.∝2 / ∝1 
selectivity of dexmedetomidine is 1620:1 whereas it is low for clonidine 
and hence dexmedetomidine is 8 times more powerful ∝2 – adrenoceptor 
than clonidine. 
 
 
47 
 
 Cardiovascular system 
  Dexmedetomidine has no effects on the heart directly. It causes a 
dose dependent increase in coronary vascular resistance and oxygen 
extraction and the supply / demand ratio is unaltered. It evokes a biphasic 
blood pressure response. A short hypertensive phase and subsequent 
hypotension and the 2 phases are mediated by 2 different ∝2 –AR 
Subtypes: the ∝-2B AR is responsible for the initial hypertensive phase.  
Hypotension is mediated by the ∝2A –AR.(62)  Younger patients with 
high level of vagal tone develop bradycardia and sinus arrest which were 
effectively treated with anticholinergic agent. 
 
Respiratory system 
  Dexmedetomidine does not produce respiratory depression even at 
high doses (63). It can be safely used in spontaneously breathing  patients 
after surgery in ICU. It maintains sedation without cardiovascular 
instability or respiratory drive depression. Hence it is used during 
weaning and extubation in trauma / surgical ICU Patients in whom 
previous attempts at weaning have failed because of agitation associated 
with hyperdynamic cardio pulmonary response (64). 
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 Central nervous system 
  Dexmedetomidine reduces cerebral blood flow and cerebral 
metabolic requirement of oxygen. Dexmedetomidine enhances 
cumulative performance and also possess sedative, analgesic and 
anxiolytic action through ∝2 –AR(65) .It reduces levels of circulating  and 
brain cetecholamines, thus balancing the ratio between cerebral oxygen 
supply and demand, reduces excitotoxicity and  improves the perfusion in 
the ischemic penumbra, hence it possess excellent neuroprotective action. 
In subarachnoid haemorrhage it reduces the levels of glutamate which is 
responsible for cellular brain injury. 
 
Endocrine and renal effects 
  Dexmedetomidine activates peripheral presynaptic ∝2–AR, thus 
catecholamine release is reduced and hence sympathetic response to 
surgery is also reduced. It is an imidazole agent but does not inhibit 
steroidogenesis when used as an infusion for short term sedation(66). 
 
Adverse Effects: 
  Side effects reported are hypotension, hypertension, nausea, 
vomiting, dry mouth, bradycardia, atrial fibrillation, pyrexia, chills, 
pleural effusion, atelectasis, pulmonary edema, hyperglycemia, 
hypocalcaemia, acidosis, etc., Transient hypertension  is produced when 
dexmedetomidine infusion is rapidly administered (Loading dose of 
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 1µg/Kg / hr if given less than 10 minutes) and this is mediated by 
peripheral ∝2B –AR vasoconstriction(67).  
 
  The occurrence of Hypotension and bradycardia is mediated by 
central ∝2A-AR, causing decrease in  noradrenaline release from the 
sympathetic nervous system. Supersensitization and up regulation of 
receptors occur during long term use, hence abrupt discontinuation not 
advised. Withdrawal symptoms of nervousness, agitation, headache and 
hypertensive crisis occur during abrupt discontinuation.       
                         
Clinical applications of dexmedetomidine premedication 
  Dexmedetomidine is used as an adjuvant for premedication since 
this drug possess sedative, anxiolytic, analgesic, sympatholytic, and 
stable homodynamic profile. Premedication dose is 0.33 to 0.67 mg /kg 
IV given 15 minutes before surgery. Oxygen consumption is decreased in 
intraoperative period and in post operative period (68).  
 
Intra operative use: 
  Dexmedetomidine attenuates the homodynamic stress response 
which occurs during intubation and extubation by sympatholysis(69). 
Dexmedetomidine potentiates anesthesic effect of all the anesthesic 
agents, thus reducing their requirement (70).  
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 Regional anaesthesia 
  Highly lipophilic nature of dexmedetomidine facilitates rapid 
absorption into the cerebrospinal fluid. It binds to ∝2 – AR of spinal cord 
for its analgesic action(79). Sensory and motor block produced by local 
anesthetics is prolonged. It is also used in intravenous regional 
anaesthesia (IVRA), brachial plexus block and intraarticularly. It is also 
given through intraarticular route in arthroscopic knee surgeries to 
improve the duration of postoperative analgesia(71).  
Sedation in ICU 
  Dexmedetomidine produces cooperative sedation. It does not 
interfere with the respiratory drive hence it facilitates early weaning from 
ventilator, thus reducing ICU stay and costs (72). Many studies have 
recommended their use for longer than 24 hrs. Their other beneficial 
effects are minimal respiratory depression, analgesic sparing effects, 
reduced delirium and agitation, and desirable cardio vascular effects. 
 
Procedural sedation  
  Dexmedetomidine is used for short term procedural sedation like 
transesophageal echocardiography(73), colonoscopy(74), awake carotid 
endarterectomy(75), shockwave lithotripsy(76), elective awake fiberoptic 
intubation (77),pediatric MRI(78). The dose is 1 µg/kg with a maintainance 
dose  of 0.2µg/kg/h. 
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 Controlled hypotension(80-81) 
  Spinal fusion surgery for idiopathic scoliosis, septoplasty and 
tympanoplastyoperations and maxillofacial surgery have been done with 
dexmedetomidine induced hypotension. 
 
Analgesia 
  Dexmedetomidine activates ∝2 –AR in the spinal cord, thus the 
transmission of nociceptive signals is reduced. It possesses significant 
opioid sparing effect. 
 
Cardiac surgery(82) 
  Dexmedetomidine reduces the extent of myocardial ischemia 
during cardiac surgery. 
 
Neurosurgery(83) 
  Dexmedetomidine possess neuro protective effect. It also 
attenuates delirium and agitation, so that postoperative neurological 
evaluation will be easier. It has a role in functional neurosurgery like 
awake craniotomy surgeries and implantation of deep brain stimulators 
for Parkinson’s disease. 
 
Obesity 
  In morbidly obese patients this drug does not cause respiratory 
depression in the dose of 0.7µg /kg intra operatively.  
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 Obstetrics(84) 
  Dexmedetomidine is also used in obstetrics due to its maternal 
hemodynamic stabilizing property. It also produces anxiolysis and 
stimulation of uterine contractions. Since it is highly lipophilic it does not 
cross placenta and hence it causes less chance of fetal bradycardia. 
 
Pediatrics 
  Recently it is used in pediatric patients for sedation during non-
invasive procedures in radiology like CT scan and MRI(85) . 
 
Other uses 
a) Used as an anti-shivering agent 
b) Used as an alternative to clonidine unresponsive patient  
c) Used in the treatment of withdrawal from benzodiazepines, 
opioids and alcohol. 
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 CLONIDINE 
 
History and chemistry(86-90) 
  Clonidine hydrochloride, an imidazoline derivative was introduced  
as a nasal decongestant and vasoconstrictor.  This  drug  is  related  to  the  
drug  called  naphazoline, still  this  has  complex  profile  of  actions.  Its 
hypotensive and bradycardia effects were first appreciated  in 1962. It is a 
centrally acting adrenergic agonist that lowers blood pressure by 
decreasing basal sympathetic system activity. it was introduced in Europe 
in1966 and subsequently in the U.S as an antihypertensive agent.(220:1 
alpha2:alpha1). 
 
Structure 
 
 
 
 
   2-(2,6_-dichlorophenylamino)-2 – imidazoline 
hydrochloride.; 
C9H9C12N3 Hcl. Molecular weight :266.56. 
 
  It is an odorless, white, bitter crystalline substance soluble in 
alcohol and water. 
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 Mechanism of action   
  Alpha-2 adrenergic agonists produce clinical effects by binding to 
alpha-2 receptors. It is a centrally acting partial adrenergic agonist 
(alpha2:alpha1=220:1).  Alpha 2 receptors densely found in  pontine 
locus ceruleus which is an important source of sympathetic nervous 
system innervations of  the forebrain and a vital modulator of vigilance. 
The sedative effect is inhibition of this nucleus. It also stimulates alpha 2 
adrenergic inhibitory neurons in the medullary vasomotor centre. All 
these leads to decreased sympathetic nervous system outflow from the 
central nervous system to peripheral tissues and manifested as peripheral 
vasodilatation and a decrease in systolic blood pressure, heart rate and 
cardiac output. Clonidine has the ability to modify the potassium channels 
in the CNS and hyperpolarize the membranes. So it reduces the anesthetic 
requirements. 
 
Neuraxial placement of clonidine inhibits substance P release and 
nociceptive neuron firing produced by the noxious stimulation. Alpha 2 
afferent terminals are situated centrally and peripherally, in the superficial 
laminae of the spinal cord and several brainstem nuclei. This suggests the 
analgesic effects of clonidine are more pronounced after neuraxial 
administration.  Clonidine synchronously decreases the cold response 
threshold while slightly increasing the sweating threshold thus suggesting 
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 that it acts on the central thermoregulatory system rather than preventing 
shivering peripherally. 
 
Pharmacological effects: 
  Intravenous clonidine can cause a transient rise followed by a fall  
in blood pressure due to its peripheral  vasoconstrictive effect on  alpha 2 
receptor  on vascular smooth muscle of skin and mucosa and decrease in 
BP is due to central effect by reduction of sympathetic outflow from CNS  
and reduction in the release of nor epinephrine at the nerve terminals . 
 
Pharmacokinetics: 
  Clonidine is rapidly absorbed after oral intake and 100% 
bioavailable. Within 60 to 90 minutes it will reach the peak plasma 
concentration. The elimination half life is around 9-12 hours.50% is 
metabolized in the liver and 50% is excreted in an unchanged form by the 
kidney. Its half life is increased in renal failure and liver failure. A 
transdermal delivery system is available in which the drug is released at a 
constant rate for about a week. Three to four days are required to achieve 
steady state concentrations. 
 
Side effects : 
The most common is sedation and xerostomia. Fatigue, weakness, 
headache, withdrawal syndrome. Pallor, weakly positive coombs test and 
fever may also rarely occur. 
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 Cardiovascular system :  
  Orthostatic symptoms, palpitation, tachycardia, bradycardia, 
conduction abnormalities (i.e, junctional bradycardia, high degree 
Atrioventricular block and sinus node arrest ) congestive heart 
failure, raynauds phenomenon and syncope.  
 
Central nervous system : 
  Nervousness, mental depression, insomnia, agitation, may 
occur. Other behavioral changes, vivid dreams or nightmares, 
hallucinations and delirium are rarely reported. 
 
Dermatological : Rash, pruritis,angioneurotic edema and urticaria, 
alopecia. 
Gastrointestinal : Nausea, vomiting,anorexia,malaise, abnormalities in 
LFT constipation and abdominal pain rarely. 
Genitourinary : Decreased sexual activity, impotence,  
Hematological : Reduced platelet count rarely.  
Metabolic : Weight gain, gynecomastia, transient 
 hyperglycemia(91) ,   increased serum CPK 
 Musculoskeletal : Myalgia, arthralgia, leg cramps. 
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 Interactions with various other pharmacological preparations : 
This  drug  may  also  like  other  ones  are  seen  to  be   reacting  
with  other      drugs   namely: 
• Tricyclic anti-depressant  drug  
• Chlorpromazine 
 
Because  of  these  specific  interactions, the  intended  anti-
hypertensive  nature  of  the  drug  may  be  very  much  reduced  and  
affected. Clonidine can cause bradycadia or AV block.  So it should be 
used with caution in patients who are on digitalis, calcium channel 
blockers,beta blockers. 
 
Toxicology; 
  Some of the studies supported the occurence of spontaneous retinal 
degeneration in albino rats treated with clonidine for more than six 
months. In some studies conducted in dogs and monkeys clonidine 
showed a high drug concentration in choroid .But in human studies they 
documented dryness of eyes only.  In electroretinography ,macular dazzle 
retinal function was normal. 
 
Over dosage;  
  Hypertension followed by fall in blood pressure, heart rate, 
respiratory rate, temperature, altered consciousness, decreased or absent 
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 reflexes, seizures, weakness and miosis. Reversible cardiac conduction 
abnormality, apnea, coma may occur. Toxic effects are developed within 
30 minutes to two hours after exposure. In paediatric patients, even  a 
small dose of 0.1mg clonidine may produce toxic effects. 
 
Antidote: 
  There is no specific antidote for clonidine. In recently ingested 
patients, gastric lavage, activated charcoal may be useful. Supportive care 
may include anticholinergic for bradycardia, IVF and vasopressors for 
hypotension and vasodilators for hypertension. Naloxone may useful for 
clonidine induced respiratory depression,hypotension coma . Dialysis is 
not much useful. 
 
Available forms: 
Formulations Brand Dosage 
Oral tablets Clonidine tablets 0.1,0.2,0.3mg 
Transdermal patch Clonidine TTS 
0.1,0.2,0.3g 
3mg/day 
Combination tablets 
Clonidine and 
Chlorthalidone 
0.1,0.2 or 0.3 mg 
clonidine+15mg 
chlorthalidone 
Injection Cloneon, duraclon 500,150,100mcg/ml 
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 Various routes of clonidine 
Route Dose 
Intranasal 2-4mcg/kg 
Intramuscular 2mcg/kg 
Oral 4-5mcg/kg 
Rectal 2.5-5mcg/kg with atropine 40mcg/kg 
Intravenous 
1-2mcg/kg bolus or 0.18-3.16 mcg/kg/hr 
infusion 
Caudal anaesthetic adjuvant 1-2mcg/kg 
Spinal anaesthetic adjuvant 1-2mcg/kg 
Epidural anaesthetic adjuvant 0.0625%bupivacaine with fentanyl 1mcg/ml 
and clonidine 0.6 mcg/ml 
Sciatic block 0.2% ropivacaine 0.4mg/kg/hr with 
clonidine 0.12 mcg/kg/hr infusion 
 
Anesthetic uses of clonidine 
  The anesthetic use of an alpha 2 adrenergic receptor agonist has 
been of recent research interest over last 20 years. 
 
Premedication  
  It reduces anaesthetic dose requirements and MAC of volatile 
anaesthetics. It can be used as premedication. In addition it also has an 
anaesthesia sparing effect. Clonidine is recommended in doses of 
4mcg/kg intranasally or orally and rectally in a dose of 5mcg/kg causes 
60 
 
 adequate sedation. Routine use of anticholinergic with clonidine reduces 
the incidence of bradycardia and hypotension. 
 
  However we have to reduce the doses of IV induction agents when 
clonidine is used as premedicant. Otherwise patient may have 
hypotension  and bradycardia after induction  during anesthesia. 
 
Its use as a premedicant is more useful in certain group of patients like 
(96,97) 
- Drug addicts and alcoholics. Most of these patients have 
withdrawal symptoms and their sympathetic system activity is high 
when compared to normal patients. 
- Patients on chronic opioid or analgesic treatment for cancer pain. 
These patients have increased analgesic requirement 
intraoperatively.(92) 
- Hypertensive patients who are vulnerable to blood pressure swings. 
 
Control of hemodynamic response:  
  The hemodynamic effects of clonidine are both central and 
peripheral. Stimulation of the peripheral sub endothelial receptor causes 
vasoconstriction transiently. 
 
  Stimulation of alpha 2 adrenergic receptors of the neurons in the 
nucleus tractus solitarius causes inhibition of nucleus of sympathetic 
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 neurons in the medulla, and reduces the baroreflex activity, decreases the 
atrial pressure leading to fall in heart rate. It is interesting to note that 
phasic activity of this reflex is preserved. So that any decrease in arterial 
pressure is followed by a significant increase in heart rate. It depresses the 
presynaptic sympathetic neurons at thoracic spinal cord level (lateral 
horn).  Local administration of neostigmine inhibits this effect. 
Hypotension effect is more in intrathecal than intravenous route. 
Vasoconstrictors (eg.phenylephrine) and anticholinergics are used to treat 
the hypotension and bradycardia. 
 
   Clonidine prevents stress response to laryngoscopy, intubation, 
extubation and surgical stimulation.  It inhibits shivering. Patients 
undergoing cardiac surgery and vascular surgery have superior control of 
hemodynamics, reduces the incidence of myocardial ischemia and 
decrease the morbidty and mortality. 
 
Post operative analgesia and regional anesthesia: (93) 
  It inhibits transmission of nociceptive stimuli in the dorsal horn of 
the spinal cord.  Clonidine has additive effect with opioids and augment 
local anesthetic blockade and prolongs the duration of anaesthesia. 
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 Epidural: 
  It can be used as whole anesthetic agent to produce epidural 
analgesia in large dose (upto2-3000mcg/day).  At this dose hypotension, 
bradycardia is common. It is more commonly used along with local 
anesthetics and opioids at a dose of 10-15 mcg/hr. 
 
Spinal: 
  Compared to morphine, intrathecal clonidine produces analgesia of 
shorter duration but without respiratory depression or urinary retention, 1-
2mcg/kg can be given along with local anaesthetics.(94,95) 
 
Caudal: 
  Clonidine prolongs duration of the block without hemodynamic 
alterations.  The recommended dose is 1-2mcg/kg. 
 
Labor analgesia: 
  Epidural clonidine can be used alone or with opioids or local 
anaesthetics. Clonidine crosses the placenta but does not affect the 
newborn. The recommended dose is 100mcg during labor. 
 
Peripheral nerve blockade: 
  Clonidine reduces the failure rate, reduces the local anaesthetic 
dose requirement and prolongs the duration of post operative analgesia. A 
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 small dose of 2-3mcg/kg is sufficient which obviously reduces the risk of 
side effects. 
 
  The quality of bier’s block (IVRA)   by clonidine with lignocaine is 
improved. Addition of 150mcg clonidine has been found to enhance the 
tolerance of the tournique.  
 
Other uses are 
∗ Prevention of emergence agitation 
∗ Decreasing minimum alveolar concentration of sevoflurane 
∗ Studies have found that oral clonidine 4mcg/kg given 105 minutes 
before induction decreased MAC values of sevoflurane for LMA 
insertion. 
∗ Postoperative nausea and vomiting (PONV). 
 
Hypotensive anesthesia 
  In cardiovascular surgery; better hemodynamic stability in patients 
posted for cardiac surgery. 
 
Post operative shivering :  
  Clonidine is effective in treating postoperative shivering in 
children. 1.5 mcg/kg is required to stop shivering in 5 minutes. 
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 Day care surgery : 
  Oral clonidine premedication and new safer local anesthetics 
ropivacaine or levobupivacaine with clonidine adjuvants as single caudal 
shots prolong analgesia with minimal side effects. 
 
Contraindication: 
Clonidine is contraindicated in 
∗ Hypovolemia 
∗ A-Vblock 
∗ Prolonged PR interval 
∗ Sinus  bradycardia 
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 MATERIALS AND METHODS 
 
STUDY DESIGN  
  Prospective randomized comparative double blinded study 
  
POPULATION  
  6O patients 
 
 INCLUSION CRITERIA  
 ASA I, II  
 Age 20 to 50  
 Unilateral upper limb orthopaedic surgeries  
 Both sexes  
 
EXCLUSION CRITERIA  
 Patient Refusal  
 Patients on adrenoreceptor agonist or antagonist therapy.  
 Suspected coagulopathy  
 Infection at the site of block  
 History of respiratory, cardiac, hepatic or renal failure.  
 Patients with medical complications like severe anemia, severe 
hypovolemia, shock, septicemia.  
 Allergy to local anaesthetics and study drug.  
 Pregnant women.  
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SAMPLE SIZE  
 Group BC (N = 30) – 35 ml of 0.357%bupivacaine + 2mcg/kg 
clonidine.  
 Group BD (N = 30) – 35 ml of 0.357% bupivacaine + 2mcg/kg 
dexmedetomidine. 
    
PRE OPERATIVE EVALUATION  
In all the patients,  
 Age  
 I.P. No  
 Body weight and  
 Baseline vital parameters were recorded.  
 
  History regarding previous anaesthesia, surgery, any significant 
medical illness, medications and allergies were recorded. Complete 
physical examination and airway assessment were done. Following 
laboratory investigations were done:  
 Haemoglobin %,  
 Blood sugar & urea  
 Serum creatinine  
 Urine analysis.  
 Chest x ray , ECG 
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  Bleeding time and clotting time  
 Screening for HIV, HbsAg  
 
STUDY METHOD  
  After getting approval from the institutional ethical committee, 
informed written consent were obtained from the patients. The patients 
were randomly allocated into two groups according to computer 
generated random numbers. Preliminaries:  
 
a) For the procedure:  
• A portable tray covered with sterile towels containing: 
• Sterile syringes –two twenty ml syringe 
• Hypodermic needles of 5 cm length,22G 
• Povidone iodine and spirit 
• Sponge holding forceps 
• Towels and towel clips 
• Sterile gauze pieces 
 
b) For emergency resuscitation: 
• The anaesthesia machine,emergency oxygen source (E type 
cylinders), pipeline 02 supply, working laryngoscopes, appropriate 
size ET tubes  
• Working suction apparatus  
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 • Oropharngeal airway 
• Intravenous fluids. 
• Drugs : thiopentone, diazepam, succinylcholine, hydrocortisone, 
atropine, adrenalin, aminophylline, mephenteramine, calcium 
gluconate and sodium bicarbonate. 
 
c)Monitors: 
• Pulse oximeter. 
• Non invasive blood pressure monitor by sphygmomanometer on 
the opposite limb. 
 
  Patients were premedicated with inj.atropine 0.02mg/kg i.m 45 
minutes before surgery. After insertion of a 18-gauge intravenous cannula 
in the contralateral arm, Ringer Lactate fluid was started. Standard 
monitoring was used during anaesthesia and surgery. HR, MAP and 
SpO2 were recorded before surgery and at regular intervals during and 
after the surgery. Procedure : patient lies supine, arms by the side and 
head turned slightly to the opposite side. 
 
∗ Identify the interscalene groove and mark the midpoint of clavicle. 
∗ with aseptic preparation , a point  of around   1.5 to 2.0 cm 
cephalad and posterior  to midpoint of clavicle,  the subclavian 
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 pulse was felt. A skin wheel was raised with local anaesthetic just 
cephalo-posterior to the pulsations. 
∗ Next ,a 22 gauge ,5cm needle ,mounted on a 20ml syringe,was 
passed through the same point,parallel to  the head and 
neck,caudally and  medially and posteriorly ,until the paresthesia 
was elicited or 1 st  rib was encountered. 
∗ If the 1st rib was encountered, the needle would be walked  over the 
first rib until a paresthesia was elicited either in the arm or hand 
∗ After conforming the  negative aspiration of blood,  drugs were  
injected by the observer who was blind to the patient group. 
∗ All patient were monitored for anaesthesia and analgesia upto 16 
hours post operatively. 
  Sensory block was assessed by sensations to pinprick on skin 
dermatomes C4toT2. Whereas motor blockade was assessed by 
movements in the thumb: 
 
• Adduction for ulnar nerve,  
• Abduction for  radial nerve,  
• Opposition for  median nerve,  
• Flexion of elbow, the   supination  and   the  pronation of   forearm 
for   musculocutaneous nerve  were  assessed. 
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   Intraoperative and post operative complications were also noted 
and recorded to know the outcome of the study. 
 
Hollmen scale was used   to examine   sensory as well as motor block.  
 
HOLLMEN SCALE:  
FOR   MOTOR BLOCK: 
∗ Normal level of   function of muscle = 1 
∗ Mild   level function weakness = 2   
∗ Moderate level function weakness =3   
∗ Total   action of muscle lost = 4  
 
Sensory block assessment:   
∗ Good   level pinprick sensation = 1  
∗ Pointed sharp weak sensation than other hand = 2 
∗ Perceived sense- blunt touch with needle=3   
∗ Nil sensation to pinprick =4      
 
   Examination was conducted every one minute  after  giving  the  
drug   and  the time taken for  initiation   of   the  motor  and  sensory  
block  was noted.  Time for onset   is explained   as level   of at least   
grade 2 in measuring hollmen’s scale. 
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   Time for  complete  block  is   defined  as  when    motor, sensory  
scores  amount   to   grade 3 according  to  hollmen  scale.  Total  time   
of  motor  block   is    explained  to  be  the  time   from the   injection  of    
the    drug   and  recovery  of   muscle power. 
 
  Total  duration  of  sensory  block  is  defined  as the time  from  
giving  the  drug   and  the  time  when patient  complaints  pain  in   the  
post operative period. 
 
STATISTICAL ANALYSIS  
Software Name :  SPSS 20 and Sigma Stat 3.5 versions  
Tests used:  
∗ One way ANOVA, 
∗ Student’s  test,  
∗ Pearson Correlation for Datas  
∗ Chi square test for consolidated figure.  
∗ p‟ value of  < 0.05 taken as significant. 
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 OBSERVATION AND RESULTS 
 
  Sixty patients with ASAI and II of either sex between 15-50 years, 
posted for upper limb surgeries under brachial plexus block by 
supraclavicular approach were selected for the study.  The study was to 
compare the efficacy of dexmedetomidine and clonidine with 
0.357%bupivacaine for brachial plexus block by supraclavicular 
approach. 
 
  In both the groups adverse effects such as nausea, vomiting, 
hypoxemia and hypotension were not observed. Age, weight of the patent 
and duration of surgery between both the groups were comparable and 
were statistically  not significant.(p>0.05). 
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 Table 1: age distribution between the two groups 
 
 Mean SD p value t value 
Group BC 34.00 7.469 
0.149 1.461 
Group BD 37.167 9.229 
 
 
Fig 7 . Comparison of age (yrs) distribution between two groups 
      
 
 
  The mean age (yrs) of the group BC was 34_+7.4 years and the 
group BD was 37.1-+9.2 years. The age distribution of these two groups 
were  statistically  not significant (p>0.05) 
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 Table 2: Comparision of sex distribution between the two groups 
 
 Male Female Total 
Group BC 17 13 30 
Group BD 16 14 30 
Total 33 27 60 
 
 
Fig 8. Comparision of sex distribution between the two groups 
 
 
  
  Comparison of sex distribution between the two groups were 
statistically not significant. 
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 Table 3 comparison between weight (Kg) of the two groups 
 
 Mean SD p value t value 
Group BC 59.533 5.981 
0.301 1.043 
GroupBD 61.2 6.386 
 
Fig 9 comparison between weight (Kg) of the two groups 
 
 
 
  The mean weight of the group BC was 59.533kg, whereas the 
mean weight of the group BD was 61.2 kg. The difference  in  weight  
between  the  two  groups  were  statistically  not  significant .(p>0.05) 
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 Table 4 Comparison of duration of surgery (min) among the two 
groups 
 Mean SD p value t value 
Group BC 100.167 10.462 
0.752 0.317 
Group BD 99.333 9.890 
 
 
Fig 10 Comparison of duration of surgery (min) among the two 
groups 
 
 
 
 
 
  The mean duration of surgical procedure in group BC was 100.16 
minutes and the mean duration of surgical procedure in group BD was 
99.33minutes. The difference between the two groups were statistically 
not significant (p>0.05) 
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 Table 5 comparison of baseline hemodynamic variables between the 
two groups 
 Group BC Group BD   
Mean SD Mean SD p value t value 
PR 83.4 5.43 83.267 5.388 0.924 0.0985 
MAP 93.5 6.474 92.900 6.375 0.719 0.362 
SPO2 98.233 0.728 98.333 0.661 0.580 0.557 
 
Fig 11. Comparison of baseline hemodynamic variables between the 
two groups 
 
 
   
  The pre operative hemodynamic variables among the two groups 
were statistically  not significant.(p>0.05) 
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Table 6Comparison of intraoperative pulse rate between two groups 
at various time intervals 
 
 Group BC Group BD 
p value t Value 
Mean SD Mean SD 
5 MIN 83.900 5.189 83.433 5.380 0.734 0.342 
10 MIN 85.233 5.380 74.933 4.226 0.001 8.246 
15 MIN 86.667 6.013 73.900 4.221 0.001 9.518 
20 MIN 87.600 5.922 71.667 5.707 0.001 10.610 
30 MIN 89.167 5.427 71.333 3.898 0.001 14.618 
45 MIN 88.800 5.774 70.167 2.902 0.001 15.794 
60 MIN 87.900 6.525 68.867 2.636 0.001 14.814 
90 MIN 88.500 5.551 71.367 2.619 0.001 15.290 
EOS 87.667 5.492 72.633 5.707 0.001 13.483 
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Fig 12.Comparison of intraoperative PR between two groups at 
various time intervals 
 
 
 
   
 Except at 5th minute, the intraoperative pulse rate values were 
lower in Group BD, when compared to Group BC. This was statistically 
significant.(p<0.05). 
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Table 7 Comparison of intra operative MAP between two groups at 
various time intervals 
 
 
Group BC Group BD 
p value t Value 
Mean SD Mean SD 
5 MIN 93.700 6.439 92.900 6.375 0.631 0.484 
10 MIN 93.400 6.317 87.533 6.163 0.001 3.641 
15 MIN 93.433 6.479 86.633 6.184 0.001 4.158 
20 MIN 93.500 6.307 85.800 6.348 0.001 4.713 
30 MIN 93.200 6.239 84.100 6.272 0.001 5.634 
45 MIN 93.067 6.777 83.367 6.483 0.001 5.665 
60 MIN 92.900 6.546 82.867 6.501 0.001 5.957 
90 MIN 93.167 6.691 83.733 6.475 0.001 5.549 
EOS 93.067 6.464 84.700 6.109 0.001 5.152 
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Fig 13. Comparison of intra operative MAP between two groups at 
various time intervals 
 
 
 
 Except at the 5th minute, the intraoperative MAP values were 
lower in Group BD, when compared to Group BC. This was statistically 
significant (p<0.05). 
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Table 8 Comparison of intraoperative SPO2 between two groups at 
various time intervals 
 
 
Group BC Group BD 
p value t Value 
Mean SD Mean SD 
5 MINS 98.200 0.714 97.933 0.828 0.187 1.336 
10 MINS 98.167 0.747 98.00 0.743 0.390 0.867 
15 MINS 97.933 0.691 98.200 0.714 0.147 -1.469 
20 MINS 97.933 0.828 98.167 0.747 0.256 -1.147 
30 MINS 98.000 0.743 97.933 0.691 0.720 0.366 
45 MINS 98.200 0.714 97.933 0.828 0.187 1.336 
60 MINS 98.167 0.747 98.200 0.714 0.860 -0.177 
90 MINS 97.933 0.691 98.167 0.747 0.214 -1.256 
EOS 97.933 0.828 97.933 0.828 1.000 0 
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Fig 14.Comparison of intraoperative SPO2 between two groups at 
various time intervals 
 
 
 
  The mean intraoperative SPO2 among the two groups were  
statistically  not significant.(p>0.05) 
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Table 9 Comparison of postoperative pulse rate between the two 
groups 
 
 
Group BC Group BD 
p value t Value 
Mean SD Mean SD 
1 H 88.167 5.547 77.00 2.779 0.001 9.859 
2 H 88.567 5.354 85.50 4.592 0.021 2.381 
4 H 88.467 5.469 88.633 5.223 0.904 -0.121 
8 H 87.900 5.435 88.967 5.461 0.451 -0.758 
12 H 87.433 6.146 88.100 5.561 0.661 -0.441 
16 H 86.533 6.410 88.067 5.942 0.341 -0.961 
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Figure 15. Comparison of postoperative pulse rate between the two 
groups 
 
 
 
  Post operative  PR  values  in  Group BD  was  lower  than  Group 
BC in the first postoperative hour(p<0.05). In the 2H, 4H, 8H, 12H,16H  
values were  statistically  not significant.   
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 Table 10 Comparison of Postoperative Mean arterial pressure 
between two groups 
 
 
Group BC Group BD 
p value t Value 
Mean SD Mean SD 
1 H 93.033 6.300 85.900 5.979 0.001 4.498 
2 H 93.200 6.272 90.600 6.095 0.109 1.623 
4 H 93.100 6.418 90.500 5.979 0.156 1.436 
8 H 92.533 6.198 91.267 6.231 0.433 0.790 
12 H 92.767 6.044 91.267 6.231 0.347 0.946 
16 H 92.833 6.035 91.500 6.191 0.402 0.845 
 
Fig 16. Comparison of Postoperative SPO2 between two groups 
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 Table 11 Comparison of Postoperative SPO2 between two groups 
 
 
Group BC Group BD 
p value t value 
Mean SD Mean SD 
1 Hr 97.933 0.828 97.933 0.691 1.000 0 
2 Hr 98.000 0.743 97.933 0.828 0.744 0.328 
4 Hr 98.200 0.714 98.000 0.743 0.292 1.063 
8 Hr 98.167 0.747 98.200 0.714 0.860 -0.177 
12 Hr 97.933 0.828 98.167 0.747 0.256 1.147 
16 Hr 97.933 0.828 97.933 0.691 1.000 0 
  
FIG 17Comparison of Postoperative SPO2 between two groups 
 
 
  Post operative spo2 values between the two groups were 
statistically not significant. 
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 Table 12 : Comparison of  Quality Of Block Between Two Groups 
 
Quality Mean SD p value t value 
 
Group BC 3.13 0.82 
< 0.001 4.52 Significant 
Group BD 3.87 0.35 
 
 
Figure 18- Comparison of Quality of Block Between Two Groups. 
 
 
 
 
  Bupivacaine dexmedetomidine group has better quality than 
bupivacaine clonidine group. 
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 Table 13Comparison of onset time of sensory block(minutes) 
 
 
Mean SD p value t value 
 
Group BC 8.47 1.04 
< 0.001 17.19 Significant 
Group BD 4.7 0.59 
 
 
Fig 19Comparison of onset time of sensory block(mt) 
 
 
 
  The mean time for onset of sensory block in Group BD was 4.7 
minutes which was lower than Group BC -8.47 minutes. This was 
statistically significant(p<0.05) 
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 Table 14Comparison of onset time of motor block between two 
groups 
 
OTMB Mean SD p' value t value 
 
Group BC 13.1 1.42 
< 0.001 11.32 Significant 
Group BD 9.63 0.89 
 
Fig 20 Comparison of onset time of motor block 
 
 
 
  The mean time for onset of motor block in Group BD was 9.63 
minutes which was lower than Group BC -13.1minutes.This was 
statistically significant(p<0.05) 
 
 
0
2
4
6
8
10
12
14
Group BC Group BD
13.1
9.63
ONSET OF MOTOR BLOCK
91 
 
 Table 15 Comparison of total duration of sensory block between two 
groups(mt) 
 
TDSB Mean SD p value tvalue 
 
Group BC 319.1 32.74 
< 0.001 25.89 Significant 
Group BD 537.8 32.67 
 
Fig 21Comparison of total duration of sensory block between two 
groups(mt) 
 
 
 
  The mean time for total duration of sensory block in Group BD 
was 537.8minutes. This was higher than the Group BC -319.1minutes.It 
was statistically significant (p<0.05). 
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 Table 16 Comparison of total duration of motor block between two 
groups 
TDMB Mean SD p value t value 
 
Group BC 222.23 17.84 
< 0.001 40.27  
Group BD 466.87 28.08 Significant 
 
 
Fig 22Comparison of total duration of motor block between two 
groups(mts) 
 
 
 
  The mean time for total duration of motor block in Group BD was 
466.87minutes. This was higher than in Group BC 222.23 minutes. It was 
statistically significant (p<0.05) 
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 Table 16Comparison of total duration of analgesia between two 
groups 
DOA Mean SD p value t value 
 
Group BC 375.23 32.6 
< 0.001 32.55 Significant 
Group BD 666.27 36.54 
 
Fig 23Comparison of total duration of analgesia between two groups 
 
 
 
  The total duration of Analgesia in Group BD was 666.27 minutes. 
This was higher than in Group BC – 375.23 minutes. It was statistically 
significant. (p<0.05). 
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 DISCUSSION 
  
  Brachial plexus block provides post operative analgesia of short 
duration, even when a long acting local anaesthetic like bupivacaine is 
used alone. Various adjuvants like opioids, midazolam, neostigmine, 
vasoconstrictors, sodium bicarbonate, dexamethasone have been used as 
an adjuvant with local anesthetics to prolong the time of analgesia,but 
they may have unwanted side effects or may be ineffective . The alpha 2 
agonists dexmedetomidine and clonidine are known to have analgesic 
effect and also enhance the effect of local anaesthetics intrathecally and 
epidurally. Alpha2 agonists produce this effect by its action on alpha 2 
adrenergic receptors found in peripheral nerves. 
 
  Here an attempt has been made to compare the efficacy of 
dexmeditomidine and clonidine as an adjuvant to bupivacaine 0.375%in 
brachial plexus block (supraclavicular approach) in terms of onset 
time,duration of analgesia and sedation.  Hemodynamic variables and 
supplementary analgesic requirements in first 24 hours were also studied. 
 
  The duration of analgesia was calculated from the end of local 
anaesthetic injection to the first complaint of pain. Following adverse 
effects were noted in the intraoperative and postoperative period.  
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 ∗ Hypotension (less than 20% reduction in MAP)  
∗ Bradycardia (less than 50 bpm)  
∗ Hypoxemia (Spo2 less than 90%)  
∗ Nausea and vomiting.  
 
  The α 2 agonists dose dependently enhance local anaesthetic 
potency and prolong its duration by combining at the α 2 receptors at the 
peripheral level. The other possible mechanisms by which the α 2 
agonists improve local anaesthetic action include 
  
1. Vasoconstriction around the site of injection. Thus the absorption 
of local anaesthetic drug will be delayed, resulting in the  
prolongation of the local anaesthetic effect.  
2. A direct action on the peripheral nerve.  Clonidine directly inhibits 
peripheral nerve action.  
 
  Clonidine and Dexmedetomidine are the currently used α 2 
receptor agonists. The usage of clonidine in brachial plexus block with 
various local anaesthetics yield conflicting results. It was found that 
clonidine prolongs the motor blockade with mepivacaine and bupivacaine 
but not with ropivacaine. 
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   The reason for this effect may be because that ropivacaine itself 
has an intrinsic vasoconstrictor effect and addition of clonidine to 
ropivacaine did not increase this vasoconstriction effect. 
Dexmedetomidine has been found to be an effective and safe adjuvant in 
many studies on neuraxial and peripheral nerve blocks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
 SUMMARY 
 
  In adult patients undergoing orthopaedic forearm and hand 
surgeries under brachial plexus block, the addition of 2μg/kg of 
dexmedetomidine to 35 ml of bupivacaine (0.357%) produces a shorter 
onset time for sensory and motor blockade. It also prolongs the duration 
of sensory and motor blockade. Postoperatively the duration of analgesia 
is prolonged with minimal reduction in pulse rate, blood pressure. 
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 CONCLUSION 
 
  The addidition of Dexmedetomidine (2μg/kg) to bupivacaine 
(0.357%) in  brachial plexus block by supraclavicular approach  results in 
a shorter onset time for sensory and motor blockade,  prolongs the 
duration of sensory and motor blockade and also the duration of 
analgesia. 
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 Muha;r;rp xg;Gjy; fbjk; 
 
Nehahspapd; ngah;:  taJ: ghypdk;:  thh;L: 
 
  
Kfthp:    tpahjp: 
 
 
kUj;Jtvz;:   mWitrpfpr;ir: 
 
 
  vdf;F ifapy; mWit rpfpr;ir nra;J nfhs;tjw;fhf 
iff;Fr; nry;Yk; euk;G kz;lyj;jpy; kaf;f kUe;J nrYj;jpf; 
nfhs;s rk;kjpf;fpNwd;. me;j kaf;f kUe;NjhL 
nlf;];nkbl;Nlhkpbd; my;yJ FNshdpbd; vd;Dk; Muha;r;rp 
kUe;ij Nrh;j;J nrYj;jpf; nfhs;s rk;kjpf;fpNwd;.  ,jdhy; 
Vw;gLk; ed;ik jPikfis kaf;f kUj;Jth; %yk; mwpe;J nfhz;L 
vd; KO rk;kjj;Jld; ahUila eph;g;ge;jKkpd;wp ,e;j 
Muha;r;rpf;F xg;Gjy; mspf;fpNwd;. 
 
,g;gbf;F 
Nehahspapd; ifnahg;gk;: 
Njjp:  
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 fOj;Jg;gFjpapy; iff;F nry;Yk; euk;G kz;lyj;jpy; gpAgptpf;Nfd; 
kw;Wk; nlf;];nkbNlhkpbd; my;yJ FNshdpbd; kUe;ij 
nrYj;Jtjw;fhd xg;Gjy; gbtk; 
 
ngah;:    taJ:    ,dk;: Mz;/ngz; 
kUj;Jtvz;:   thh;L:    tpahjp: 
mWitrpfpr;ir: 
 
tpsf;fk;: 
  ifapy; mWitrpfpr;ir nra;Ak; NghJ> fOj;Jg;gFjpapy; cs;s iff;F 
nry;Yk; euk;G kz;lyj;jpy;> Ggpthifapd; vd;Dk; kaf;f kUe;jpid Crpapd; 
%yk; nrYj;JtJ ifia czh;tpof;f nra;Ak; Kiwfspy; xd;whFk;.  
,jdhy; mWit rpfpr;ir nra;Ak; NghJ if czh;r;rpaw;W ,Uf;Fk;.  
Ggpthifapd; vd;Dk; kaf;f kUe;NjhL nlf;];nkbNlhkpbd; my;yJ 
FNshdpbd; (My;gh 2 mNfhdp];l;) vd;Dk; Muha;r;rpf;fhd kUe;ij 
nrYj;Jtjpdhy; Vw;gLk; gad;fs;> gpd;tpisTfs; njspthf tpsf;fp 
$wg;gl;lJ. 
 
gad;fs;: 
 Ggpthifapd; kUe;NjhL nlf;];nkbNlhkpbd; my;yJ FNshdpbd; kUe;ij 
Nrh;j;J nfhLf;Fk; NghJ> 
 rPf;fpukhf if czh;r;rpaw;WNghFk;. 
 mWitrpfpr;ir Kbe;j gpd;dh; $Ljy; Neuk; ifapy; typ ,y;yhky; 
,Uf;Fk;. 
 
khw;Wrpfpr;ir: 
  fOj;Jg;gFjpapy; kaf;f kUe;jpid nrYj;jhky;> KO kaf;fk; 
(n[duy; md];jP]pah) nfhLj;J mWitrpfpr;ir nra;Ak; Kiw gw;wp vdf;F 
njhptpf;fg;gl;lJ. 
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 gpd;tpisTfs;: 
 kaf;f kUe;jpid nrYj;Jk; NghJ gpd;tUk; gpd;tpisTfs; gw;wp vdf;F 
njhptpf;fg;gl;lJ. 
 
 kaf;f kUe;ij fOj;Jg; gFjpapy; nrYj;Jk; NghJ> mJ jw;nrayhf 
,uj;j ehsq;fSf;Fs; nrd;W jiyRw;Wjy;> glglg;G> ,jaj;jpd; Jbg;G 
mjpfkhFjy;> kaf;fk; miljy;> typg;G Nghd;wit tuyhk;.  me;j 
ghjpg;Gfs; kUe;Jfs; %yk; rhpnra;ag;gLk;. 
 nlf;];nkbNlhkpbd; kw;Wk; FNshdpbd; ,ja Jbg;gpd; msitAk;> 
,uj;j mOj;jj;ijAk; Fiwf;fyhk;.  the;jpVw;gLj;jyhk;.  mjw;F jf;f 
khw;W kUe;Jfs; jug;gLk;. 
 
mWitrpfpr;irf;fhd xg;Gjy;: 
o vdf;F ed;F Ghpfpd;w nkhopapy; jkpopy; vdJ tyJ/,lJ ifapy; 
mWitrpfpr;ir nra;Ak; NghJ kaf;f kUe;jhd Ggpthifapd; kw;Wk; 
nlf;];nkbNlhkpbd; my;yJ FNshdpbd; kUe;jpid fOj;Jg;gFjpapy; 
nry;Yk; euk;G kz;lyj;jpy; nrYj;Jtjw;fhd Kiw kw;Wk; fhuzk;> 
gad;fs;> gpd;tpisTfs;> gw;wp vdf;F tpsf;fg;gl;lJ.  ehd; mij 
Ghpe;J nfhz;Nld;. ahUila eph;g;ge;jKkpd;wp ,e;j kaf;f kUe;J 
nrYj;Jk; Kiwf;F ehd; xg;Gjy; mspf;fpNwd;. 
o vdf;F ,e;jkaf;fkUe;ijnrYj;Jk; NghJ vjph;ghuhj epiyik 
ntspg;glyhk; vd;gJ gw;wpAk; mjw;F Njitg;gLk; $Ljy; / vjph;ghuhj 
mtru rpfpr;ir Kiwfs; nra;a Ntz;baJ tuyhk; vd;gJ gw;wpAk; 
tpsf;fg;gl;lJ.  vdNt kUj;Jth; Njitnadf; fUJk; khw;W 
kUe;Jfs; nrYj;jTk; kw;Wk; rpfpr;ir Kiwfs; nra;aTk; ehd; 
mDkjp mspj;J tpz;zg;gpf;fpNwd;. 
o vdf;F mspf;fg;gLk; ,e;j rpfpr;ir Kiwia vdJ milahsk; 
my;yJ tpguq;fs; njhpahj tifapy; gpwh; ghh;itaplTk;> Gifg;glk;> 
tPbNah vLf;fTk; mDkjpg;gJld; mtw;iw kUj;Jtj;jpw;Fk;> 
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 Muha;r;rpf;Fk; kw;Wk; gapw;rpf;Fk; gad;gLj;jpf; nfhs;s xg;Gjy; 
mspf;fpNwd;. 
o vdf;F Nfs;tpfs; Nfl;gjw;F tha;g;G mspf;fg;gl;lJ.  mjw;fhd 
tpsf;fKk; jug;gl;lJ.  ,e;j xg;Gjy; gbtj;ij ehd; gbj;J ghh;j;J 
mjd; tpguq;fis mwpe;J ahUila J}z;Ljypd;wp vdJ Ra 
tpUg;gj;Jld; ,e;j gbtj;jpy; ifnahg;gk; nra;Js;Nsd;. 
 
Nehahsp /cwtpdh; ifnahg;gk;: 
ngah;: 
cwTKiw:      Njjp: 
 
kUj;Jth; jPh;khdmwptpj;jy;: 
 ehd; ,e;j kaf;fkUe;Jfs; nrYj;jg;gLk; tpjk;> tpisTfs;> ghjpg;Gfs;> 
gad;fs; kw;Wk; khw;W Kiwfs; gw;wp tpsf;fpAs;Nsd; vd;gij ,jd; 
%yk; njhptpf;fpd;Nwd;.  ehd; Nehahspf;F Nfs;tp Nfl;gjw;fhd tha;g;ig 
nfhLj;J mjw;F gjpy; mspf;fpNwd;. 
 
kUj;Jthpd; ifnahg;gk;: 
kUj;Jthpd; ngah;:     Njjp: 
rhl;rp tpguk;: 
ifnahg;gk;: 
ngah;:       Njjp: 
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 PROFORMA 
 
Case NO-                                                                            I.P-no-  
NAME : 
ADDRESS  : 
AGE  :                
 SEX   :                             
D.O.ADMISSION :  
HISTORY IN BRIEF :  
CLINICAL DIAGNOSIS/ INDICATION :  
 
EXAMINATION IN BRIEF :  
 Vitals  
∗ PULSE                  
∗ B.P-                       
∗ AIRWAY-ASSESSMENT  
 SYSTEMIC EXAMINATION  
 BASELINE HAEMODYNAMICS :  
∗ PR:                        
∗ BP:                                                 
∗ SPO2:  
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 INVESTIGATIONS 
∗ COMPLETE BLOOD COUNT          
∗ RBS 
∗ BLOOD UREA SERUM CREATININE    
∗ BT CT                              
 
URINE EXAMINATION- ALBUMIN SUGAR MICROSCOPY  
CHEST X-RAY : 
 
ECG   : 
 
ASA GRADING :  
 
SURGICAL PROCEDURE :  
 
DURATION :  
 
PARAMETERS OBSERVED-  
1. Onset time for sensory block -  
2. Onset time for motor block -  
3. Total duration of sensory block -  
4. Total duration of motor block -  
5. Duration of analgesia -  
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 Adverse Effects  
∗ Nausea +/-  
∗ Vomiting +/-  
∗ Bradycardia+/-  
∗ Hypotension +/-  
∗ Hypoxemia +/- 
 
Intra operative monitoring 
 
Time After Block PR MAP SPO2 
5min    
10min    
15 min    
20 min    
30 min    
45 min    
60 min    
90 min    
EOS    
 
 
 
 
121 
 
  
Post operative monitoring 
 
Time After Surgery PR MAP SPO2 
1H    
2H    
4H    
8H    
12H    
16H    
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1 40 F 61 k wire fixation 88 98 99 88 90 94 90 92 94 95 96 97 98 97 96 98 98 97 96 96 96 97 98 98 97 98 97 98 98 97 120 97 96 95 93 92 90 95 96 97 95 96 96 97 98 97 98 98 97 3 7 14 260 210 356
2 29 F 64 orif with plate osteosynthesis 86 97 97 87 88 90 91 93 96 89 88 90 97 97 98 99 98 97 97 97 97 98 99 98 98 97 98 99 98 98 115 90 88 89 91 93 95 96 95 96 95 96 96 98 97 98 99 98 98 2 8 13 276 204 341
3 33 F 53 orif with asian dcp 80 98 98 83 85 88 90 92 94 95 93 90 98 98 99 97 97 98 98 98 98 98 97 97 99 98 98 97 97 99 100 90 90 92 93 91 93 97 98 97 96 97 97 99 98 98 97 97 99 3 8 14 305 242 360
4 37 M 50 orif with plate osteosynthesis 86 98 98 86 88 89 90 92 92 93 94 95 98 98 99 100 97 98 98 99 99 98 99 99 97 98 98 99 99 97 90 95 96 97 94 93 92 98 99 100 99 99 99 97 98 98 99 99 97 4 7 12 355 203 403
5 25 M 52 deroofing and curettage 87 83 99 88 89 90 91 92 91 94 92 90 83 85 84 84 83 82 83 83 85 98 98 98 97 97 98 98 98 97 95 90 92 93 94 95 96 82 83 81 82 82 82 97 97 98 98 98 97 2 9 14 286 200 307
6 34 M 59 orf with plating 79 98 98 79 80 82 81 84 86 83 87 80 98 97 96 97 99 99 98 98 98 99 99 99 98 97 99 99 99 98 135 80 84 82 78 78 77 98 99 100 99 100 99 98 97 99 99 99 98 4 9 14 358 236 410
7 39 F 57 buttress plating with k wire fixation 76 99 99 76 79 80 78 84 86 87 88 84 99 99 100 99 97 98 99 99 99 98 98 98 99 98 98 98 98 99 90 84 85 87 88 89 90 98 97 96 95 94 96 99 98 98 98 98 99 4 7 12 320 205 384
8 34 M 67 orif with asian dcp 89 98 98 89 90 93 94 95 93 92 90 90 98 98 99 100 98 99 98 99 98 97 99 98 99 98 97 99 98 99 95 90 91 92 93 95 96 99 100 99 98 97 98 99 98 97 99 98 99 4 10 15 342 228 418
9 34 F 69 orif with plate osteosynthesis 80 100 97 81 80 84 83 84 83 88 89 90 100 99 100 99 98 99 98 99 98 98 97 97 97 99 98 97 97 97 110 90 90 88 85 86 83 98 97 99 98 98 98 97 99 98 97 97 97 4 11 15 356 231 388
10 48 M 63 orif with narrow dcp 88 102 98 88 90 94 93 95 92 90 89 90 102 102 103 102 100 101 101 102 100 99 97 98 99 99 99 97 98 99 105 90 88 90 91 87 86 100 100 99 98 98 98 99 99 99 97 98 99 3 9 13 312 220 376
11 22 F 60 ORIF with k wire fixation 83 95 99 83 85 84 87 90 92 90 90 88 95 96 97 96 94 95 95 96 95 98 97 98 99 97 98 97 98 99 100 88 90 91 92 93 86 95 94 93 94 95 95 99 97 98 97 98 99 3 9 14 302 236 386
12 26 M 51 ORIF with asian DCP 78 92 98 78 80 79 80 82 80 78 79 80 97 93 90 91 93 94 93 92 92 98 99 98 97 99 98 99 98 97 90 80 81 78 77 76 7 92 93 94 92 92 92 97 99 98 99 98 97 2 8 12 289 203 334
13 34 F 65 ORIF with plate osteosynthesis 72 94 98 73 74 78 80 84 88 84 83 82 94 95 94 93 95 92 93 93 94 99 99 99 98 99 99 99 99 98 90 82 82 80 78 77 79 94 94 93 93 93 93 98 99 99 99 99 98 2 9 14 276 208 322
14 38 M 68 orif with narrow dcp 84 93 99 84 85 88 90 89 86 87 88 88 93 92 92 93 95 94 93 92 92 99 98 98 98 97 99 98 98 98 90 88 90 89 88 90 90 92 91 90 90 91 91 98 97 99 98 98 98 4 10 15 348 256 402
15 24 M 66 orif with plate osteosynthesis 89 96 99 89 90 92 93 94 90 94 93 93 96 96 95 94 92 94 96 98 98 99 98 97 98 97 98 98 99 97 100 93 94 95 96 95 94 95 94 95 94 95 94 97 98 98 98 99 97 4 9 14 318 210 396
16 30 F 54 ORIF with plate osteosynthesis 83 97 98 84 88 89 90 92 96 98 94 93 97 96 97 96 98 97 97 98 97 99 99 97 99 97 99 99 97 99 95 96 97 95 93 92 90 96 97 96 96 96 96 99 97 99 99 97 99 3 8 12 305 207 386
17 32 F 56 k wire fixation 90 99 99 90 92 93 95 94 92 95 96 96 99 100 99 98 99 98 99 99 99 98 98 97 99 98 98 98 97 99 90 98 98 97 95 93 90 99 100 99 98 98 98 99 98 98 98 97 99 3 8 13 300 203 376
18 36 M 59 ORIF With plate osteosynthesis 92 90 98 92 91 90 88 89 93 94 96 98 90 89 88 90 89 90 89 89 90 97 98 97 98 98 97 98 97 98 110 98 98 96 90 87 85 90 89 88 90 90 98 98 98 97 98 97 98 4 7 11 366 268 396
19 42 F 53 orif with asian dcp 88 94 97 88 90 9 92 93 96 97 98 90 94 95 96 95 93 95 95 95 99 99 99 98 97 98 99 99 98 97 100 90 88 90 87 86 85 95 94 95 94 93 94 97 98 99 99 98 97 2 9 14 288 198 340
20 47 M 56 orif with plate osteosynthesis 72 82 99 74 76 77 75 76 78 79 80 78 83 82 84 85 81 80 80 80 80 99 98 99 98 98 99 98 99 98 90 78 77 80 84 83 80 80 81 82 80 80 80 98 98 99 98 99 98 4 8 12 334 238 398
21 32 F 52 orif with narrow dcp 76 90 98 78 76 74 78 80 77 75 79 80 90 92 93 91 93 89 90 9 90 98 97 97 99 98 98 97 97 99 95 89 84 78 80 74 72 93 90 91 92 89 90 99 9 9 97 97 99 3 9 14 328 225 386
GROUP BUPIVACAINE - CLONIDINE
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22 38 M 58 oblique osteotomy and k wire fixation 86 84 99 89 88 86 87 89 85 83 89 89 84 83 84 83 82 83 83 83 82 98 98 97 98 99 98 98 97 98 100 90 92 87 88 90 86 83 84 84 84 85 84 98 99 98 9 97 98 2 9 14 357 240 394
23 34 M 60 orif with plate osteosynthesis 87 95 97 87 90 88 89 92 97 80 88 86 95 94 93 94 94 93 93 93 93 97 97 97 98 97 97 97 97 96 95 86 88 87 86 85 84 95 96 95 94 95 95 96 97 97 97 97 96 3 9 15 296 205 346
24 24 M 53 orif with dcp 80 96 99 80 78 76 80 84 80 82 84 83 96 95 94 95 94 92 95 94 95 99 98 98 98 99 99 98 98 98 105 83 85 88 85 80 82 95 97 96 95 94 95 98 99 99 98 98 98 2 8 12 287 215 308
25 33 M 69 orif 86 100 99 86 85 ### 92 88 88 87 87 86 100 99 98 99 100 100 98 99 98 99 98 98 97 99 99 98 98 97 100 86 88 90 92 93 90 98 98 99 98 99 98 97 99 99 98 98 97 3 7 10 306 232 378
26 21 M 70 orif with asian dcp 79 82 98 99 83 85 90 87 83 76 77 78 82 8 80 81 83 80 81 82 82 98 99 98 98 98 98 99 98 98 110 78 80 82 83 85 87 82 83 82 81 82 82 98 98 98 99 98 98 4 7 11 352 229 426
27 33 M 65 orif with plate osteosynthesis 80 97 97 80 82 83 84 85 86 87 85 84 97 96 95 96 98 97 97 98 98 97 98 99 98 97 97 98 99 98 90 84 85 87 88 89 90 98 98 97 98 99 98 98 97 97 98 99 98 3 10 15 343 218 380
28 50 F 61 orif with narrow dcp 80 80 99 80 82 84 85 88 83 82 84 86 80 89 80 8 81 80 79 80 80 99 98 98 98 99 99 98 98 98 100 86 87 88 89 90 88 82 81 80 81 82 82 98 99 99 98 98 98 4 8 11 380 243 418
29 28 F 56 orif with plate osteosynthesis 89 97 98 89 90 96 97 95 92 88 85 86 97 96 98 98 94 96 96 95 96 98 97 98 98 98 98 99 98 98 105 86 85 84 80 78 76 96 97 98 96 96 96 98 98 98 99 98 98 4 8 12 354 228 402
30 43 M 59 orif with plate osteosynthesis 89 81 98 89 93 95 97 99 95 95 94 90 81 83 82 81 82 80 81 80 80 99 99 98 98 98 99 99 98 98 95 90 88 87 86 88 90 80 81 82 80 82 82 98 98 99 99 98 98 2 9 12 274 226 340
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1 30 F 57 ORIF with plate osteosynthesis 76 98 99 77 71 68 59 83 78 73 71 74 98 92 91 90 89 89 88 88 89 98 97 99 99 99 98 99 99 98 100 79 86 95 93 92 90 90 95 95 94 95 96 99 98 97 99 99 99 3 4 9 478 418 640
2 50 F 65 k wire fixation 86 89 99 85 76 76 73 67 66 64 68 73 89 84 83 82 80 79 79 80 82 99 98 98 98 98 99 98 98 99 90 80 94 95 96 95 94 83 87 87 88 88 83 98 99 98 98 98 98 4 4 9 484 420 647
3 40 M 69 ORIF with plate osteosynthesis 87 93 98 87 78 78 77 73 72 70 72 71 93 88 87 86 84 83 82 82 83 99 98 97 99 98 99 97 99 99 95 78 88 90 87 86 85 84 90 91 92 92 93 98 99 98 97 99 98 4 5 10 540 478 672
4 49 M 66 ORIF with asian DCP 80 81 98 81 73 72 70 69 68 66 70 70 81 76 75 73 71 70 70 71 72 97 99 98 97 97 97 98 97 97 100 72 77 80 84 83 80 73 79 80 80 80 82 97 97 99 98 97 97 4 4 10 536 480 689
5 37 M 58 buttress platng with k wire fixaton 86 90 98 87 76 76 74 66 65 63 67 72 90 84 84 83 81 80 79 79 80 99 99 99 97 98 99 99 97 99 90 78 83 96 90 87 85 84 88 89 90 89 90 98 99 99 99 97 98 4 5 10 546 486 692
6 31 M 59 ORIF with asian DCP 79 84 97 80 70 70 69 65 67 69 71 72 84 79 78 77 76 75 74 74 75 99 97 98 97 98 99 98 97 99 105 77 90 95 93 92 90 76 81 82 82 82 84 98 99 97 98 97 98 4 5 10 538 438 684
7 23 F 60 ORIF with plate osteosynthesis 80 95 98 78 71 69 59 78 70 71 72 73 95 90 89 88 86 85 84 85 85 97 99 98 99 98 97 98 99 97 100 74 86 88 87 82 90 86 92 92 93 92 94 98 97 99 98 99 98 4 5 9 498 428 645
8 26 M 55 ORIF with narrow DCP 80 96 99 82 72 72 71 70 70 68 70 71 96 91 90 90 88 87 87 88 88 98 99 99 99 99 98 99 99 98 110 79 90 92 93 91 93 89 94 94 95 95 96 99 98 99 99
99 99 4 5 9 520 439 656
9 33 F 50 ORIF with k wire fixation 89 100 99 90 80 79 77 73 72 70 72 71 100 94 94 93 92 91 90 90 90 98 97 99 98 98 98 99 98 98 90 74 85 95 94 93 92 92 97 97 98 98 99 98 98 97 99 98 98 4 5 10 543 457 668
10 38 M 51 ORIF with asian DCP 89 82 98 87 79 77 75 72 72 71 72 73 82 77 76 75 73 72 71 73 75 97 98 98 98 99 97 98 98 97 100 76 84 85 87 88 89 77 81 81 82 83 83 99 97 98 98 98 99 3 4 8 496 410 630
11 43 F 57 ORIF with plate osteosynthesis
88 97 99 88 77 76 73 67 66 64 68 73 97 92 91 90 88 88 87 88 90 99 97 99 99 97 99 99 99 99 105 76 90 88 89 91 93 92 96 95 96 95 97 97 99 97 99 99 97 4 4 9 521 486 721
12 28 M 56 ORIF with narrow DCP 86 80 98 86 78 77 76 74 73 72 78 80 80 75 74 73 72 71 70 72 74 99 98 98 98 97 99 98 98 99 95 80 80 84 83 78 78 76 79 80 78 79 80 97 99 98 98 98 97 4 5 10 539 468 680
13 29 F 66 ORIF with plate 
osteosynthesis
80 97 99 81 72 72 71 70 70 69 69 69 97 92 91 90 88 87 87 88 89 98 98 97 98 97 98 97 98 98 120 74 89 91 92 93 96 90 95 96 96 96 97 97 98 98 97 98 97 4 4 9 510 466 674
14 21 M 68 k wire fixation 86 81 99 87 79 78 77 74 72 70 72 73 81 76 75 74 73 72 72 72 73 97 98 99 99 98 97 99 99 97 115 76 87 89 88 90 90 74 79 80 80 80 81 98 97 98 99 99 98 4 4 9 505 460 642
15 46 F 69 k wire fixation 83 98 98 84 78 76 75 74 7 70 75 77 98 92 91 90 89 88 88 88 89 98 98 99 98 99 98 99 98 98 100 78 88 90 87 85 90 90 96 96 97 96 98 99 98 98 99 98 99 4 4 8 514 462 634
16 45 M 68 ORIF with plate osteosynthesis 79 97 98 79 73 72 70 69 68 66 70 70 97 92 91 90 88 88 88 89 90 99 98 98 97 97 99 98 97 99 90 73 78 79 80 82 84 91 95 94 95 96 95 97 99 98 98 97 97 4 4 9 520 474 656
17 31 F 67 ORIF with asian DCP 76 96 99 75 72 70 68 66 69 68 70 71 96 91 90 90 88 87 87 90 90 98 99 98 98 97 98 98 98 98 95 72 76 78 80 85 88 91 94 94 95 96 96 97 98 99 98 98 97 4 4 9 518 447 645
18 50 F 66 ORIF with plate osteosynthesis 89 97 98 89 80 78 77 73 72 70 72 72 97 90 89 89 87 87 87 90 90 96 97 97 97 97 96 97 97 96 130 74 84 90 92 93 94 91 94 93 94 95 97 97 96 97 97 97 97 4 5 11 549 434 677
19 46 M 70 deroofing and curretage 80 97 98 79 72 72 71 70 70 69 69 69 97 92 91 90 87 88 88 89 90 98 99 99 98 98 98 99 98 98 90 74 86 87 94 93 92 90 95 95 96 96 97 98 98 99 99 98 98 3 5 10 538 478 628
20 22 M 60 ORIF 88 82 98 88 79 78 75 73 73 72 71 72 82 77 76 75 73 72 72 75 77 97 99 99 98 98 97 99 98 97 90 80 84 93 94 95 96 78 80 79 80 80 81 98 97 99 99 98 98 4 5 10 560 480 639
21 40 F 70 buttress platng with k wire fixaton 83 97 98 83 75 75 74 73 72 70 71 73 97 92 91 90 89 88 88 89 90 98 98 98 99 98 98 98 99 98 105 80 84 82 78 78 77 91 95 95 96 96 96 98 98 98 98 99 98 4 5 10 570 487 651
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22 41 M 56 ORIF with asian DCP 78 98 97 77 70 70 69 66 64 64 68 69 98 93 92 92 90 89 88 89 89 98 97 97 98 99 98 97 98 98 100 76 85 88 89 88 88 90 95 96 96 97 97 99 98 97 97 98 99 4 4 9 568 490 670
23 50 M 54 ORIF with plate osteosynthesis 72 100 99 73 64 63 61 68 68 70 72 72 100 94 93 92 90 90 89 90 90 98 99 99 98 98 98 99 98 98 95 80 91 93 92 95 96 91 97 98 99 100 101 98 98 99 99 98 98 4 6 12 549 488 683
24 45 F 68 ORIF with narrow DCP 84 101 98 84 74 73 72 69 68 66 69 72 101 94 93 92 90 89 89 90 90 98 98 98 99 98 98 98 99 98 90 78 90 88 85 86 83 91 97 98 98 98 100 98 98 98 98 99 98 4 5 10 620 534 756
25 47 M 69 ORIF with k wire fixation 89 98 98 90 80 78 77 73 72 70 72 71 94 90 89 88 85 85 84 85 88 98 98 99 99 98 98 99 99 98 90 79 88 90 91 87 86 89 92 93 94 93 94 98 98 98 99 99 98 4 6 11 608 512 788
26 40 F 53 ORIF with asian DCP 83 98 97 84 75 74 72 70 70 69 73 74 91 85 84 83 82 80 80 79 80 97 98 97 98 98 97 97 98 97 95 82 90 91 92 93 85 8 88 88 88 89 90 98 97 98 97 98 98 4 5 10 587 491 654
27 38 F 54 ORIF with asian DCP 90 93 99 90 79 78 77 74 72 70 72 73 93 87 86 86 85 84 83 83 85 98 97 98 99 98 98 98 99 98 100 74 78 81 77 76 74 86 91 90 91 92 92 98 98 97 98 99 98 4 5 11 560 486 660
28 21 F 55 ORIF with plate osteosynthesis 92 92 99 91 80 79 78 74 73 72 78 79 92 87 87 86 85 84 83 83 84 99 98 98 97 97 99 98 97 99 95 79 80 82 98 81 80 85 90 90 89 90 92 97 99 98 98 97 97 4 5 10 538 470 643
29 35 M 59 ORIF with narrow DCP 88 95 99 89 78 76 75 74 71 70 75 77 95 89 88 88 86 85 84 84 85 97 98 98 99 99 97 98 99 97 90 80 90 89 88 90 90 86 92 92 93 93 94 99 97 98 98 99 99 3 5 9 537 467 628
30 40 M 61 ORIF with plate osteosynthesis 72 96 99 72 67 65 58 73 71 70 72 73 96 91 90 89 88 88 88 89 89 97 97 98 98 98 97 98 98 97 110 78 84 95 96 95 94 90 94 94 93 94 95 98 97 97 98 98 98 4 5 9 544 472 636
